Finex logo
Finex Intelligence

Market Signal Briefing

Wire-ready dashboard awaiting your first source connection.

Last news saved at Mar 30, 13:54 4d ago Cron last ran Mar 30, 13:54 4d ago Awaiting first source
Switch language
91,488 Stories ingested Auto-fetched market intel nonstop.
0 Distinct tickers Add sources to start tracking symbols
Trending sources Waiting for fresh intel
Hot tickers Surfacing from current coverage
Details Saved Published Title Source Tickers
2026-01-12 13:09 2mo ago
2026-01-12 07:15 2mo ago
Bitcoin fails haven test as Justice Dept. subpoenas Powell: Crypto Daybook Americas cryptonews
BTC
Your day-ahead look for Jan. 12, 2026
2026-01-12 13:09 2mo ago
2026-01-12 07:15 2mo ago
Aave and Morpho lead lending recovery in January after October crash cryptonews
AAVE MORPHO
On-chain lending revived in January, showing signs of recovery from crypto insiders. Aave remains the leading lending hub, expanding available liquidity. 

On-chain lending is picking up in the new year, signaling robust activity from crypto natives. Lending has drawn in whales, becoming a source of liquidity for the on-chain economies of Ethereum, Solana and a few smaller chains. 

DeFi lending expanded in the past month, with the strongest growth since the October crash. | Source: Token Terminal Total ecosystem lending grew in the past three weeks, after months of sliding following the liquidation event on October 11, 2025. DeFi lending did not see dramatic liquidations, as the ETH collateral levels were set much lower. Despite this, the worsened market sentiment prevented lending from expanding. 

Aave and Morpho lead lending expansion Aave and Morpho retained the biggest share of DeFi lending due to their economic models. Aave relied on its legacy status and high liquidity in key vaults, while Morpho expanded due to curated lending pool managers. 

Aave has also grown its dominance from 8% to over 28% in the past two years, even growing during the bear market. 

In early 2026, active loans expanded to $36.6B, up $2.1B from December’s levels. This is the highest monthly growth since the drawdown began in October. Aave contributed $1.1B to the growth for the past month, while Morpho expanded its lending by $450M, based on TokenTerminal data. 

Total liquidatable ETH lending has grown to $2.2B, after spending months at around $1B. Most of the loans on Aave, Sky Protocol and other platforms are liquidatable at levels under $1,800 per ETH, with only a small share of loans above $3,000.

Ethereum remains the main lending venue The Ethereum ecosystem remains the main lending venue, gaining support as ETH returned above $3,000. While Solana-based lending is growing, the pace and baseline levels are still much lower compared to Ethereum’s influence.

Based on DeFiLlama data, lending protocols lock in $66.91B, with a slow recovery for the past few weeks. Lending growth is not yet exponential, but points to expanding influence for the top protocols. 

Lending also creates over $28M in weekly fees, boosting Ethereum’s economy. Ethereum increased its value locked to over $72B, up from $64B in November. A recovery of DeFi may also translate into stronger ETH gains. 

In 2026, the Ethereum ecosystem may also get a boost from treasury company deposits, including staking and liquid staking. The newly issued tokens may be used within the Ethereum ecosystem, depending on the treasury company’s risk appetite. 

Lending has already displaced DEX trading as the top Ethereum activity, with liquid staking coming in second. Loan activity signals both demand for passive income and demand for additional liquidity. 

For now, the market is not yet fully recovered, but DeFi activity serves as a signal for an eventual ETH recovery.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.
2026-01-12 13:09 2mo ago
2026-01-12 07:16 2mo ago
XRP Breaks Free — $2 Support Turns Bullish cryptonews
XRP
XRP has confirmed a bullish impulsive leg after successfully defending the $2.00 demand zone, signaling potential continuation.

Brian Njuguna2 min read

12 January 2026, 12:16 PM

Source: ShutterstockXRP Surges After Defending $2.00 Demand Zone, Eyes Next Key ResistanceAccording to market analyst Tektonic, XRP has delivered a strong impulsive move after defending the crucial $2.00 demand zone. The cryptocurrency is currently trading around $2.04, consolidating after breaking out of the descending trendline that had previously capped momentum. 

Source: CoinCodex Well, this breakout signals a potential shift in market structure, suggesting that XRP may be entering the early stages of a bullish reversal.

The immediate level of resistance sits at $2.41, marking the next key zone to watch. A decisive break above this level would likely confirm continuation toward higher targets, potentially reigniting broader market optimism. 

Conversely, failure to sustain demand could expose XRP to downside risk, with support zones in the $1.77-$2.00 range acting as critical buffers for traders.

Tektonic highlights that current market dynamics are favorable for bullish continuation. The recent consolidation above the $2.00 demand zone indicates that buyers remain active, absorbing selling pressure and positioning for potential upside. This behavior reflects a classic accumulation phase, where momentum builds quietly before a larger trend emerges.

Notably, $2.41 should be given a keen eye because a clean breakout and retest could trigger a sustained uptrend, boosting market confidence. A rejection, however, would put the $2.00 demand zone to the test, which has held strong so far.

From a structural perspective, XRP’s price action demonstrates a textbook early-stage bullish reversal. The descending trendline breakout not only removes a key barrier but also signals that market sentiment is gradually shifting in favor of buyers. Momentum indicators support this narrative, suggesting that XRP may have room to extend its gains if demand zones continue to hold firm.

ConclusionXRP’s strong defense of $2.00 and breakout above its descending trendline signal bullish potential. Immediate resistance sits at $2.41, while the $1.77–$2.00 zone offers key support. Traders will watch whether this move sparks a sustained uptrend or remains a short-term impulse.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Brian Njuguna is a seasoned crypto journalist at Coinpaper, specializing in blockchain innovation, market trends, and regulatory developments. With a background in economics and years of experience covering the digital asset space, Brian delivers sharp, data-driven insights that cut through the hype. His reporting bridges global crypto narratives with emerging market perspectives, making complex topics accessible to a wide audience.

Read more about

Latest Cryptocurrencies News TodayXRP (Ripple) News
2026-01-12 13:09 2mo ago
2026-01-12 07:18 2mo ago
Dogecoin price forecast: DOGE fails to hit $0.145 amid low retail demand cryptonews
DOGE
The crypto market is currently undergoing a choppy price action as neither the bulls nor the bears seem to be in control at the moment.

Bitcoin, the leading cryptocurrency by market cap, is trading at $90,368, down by less than 1% in the last 24 hours. 

Dogecoin’s DOGE is the second-worst performer among the top 10 cryptocurrencies by market cap, after losing 2.5% of its value.

At press time, DOGE is now trading at $0.1361 and could record further losses in the near term. 

DOGE stays below $0.14 amid falling retail demand Copy link to section

DOGE has lost 7% of its value in the last seven days, making it the worst performer among the top 10 cryptocurrencies.

Its bearish performance comes amid falling retail demand and minor ETF inflows.

According to CoinGlass, Dogecoin’s futures Open Interest (OI) currently stands at $1.73 billion, down from the $1.96 billion recorded a week ago.

The declining OI indicates that retail demand for the cryptocurrency is falling, with more traders choosing to stay out than bet on Dogecoin’s price.

If the downward trend persists, signaling low retail demand, price recovery could be a pipe dream. 

The declining OI could see DOGE’s price retest the December low of $0.1161 over the next few days or weeks. 

The bearish performance was also supported by poor ETF inflow.

On Friday, Dogecoin spot ETFs recorded a minor inflow of nearly $404,000 despite the heightened volatility in the market.

According to SoSoValue, US spot Dogecoin ETFs posted the largest inflow since launch, $2.3 million on January 2, followed by the second-largest, $1.6 million on January 5th.

The declining ETF inflow suggests that institutions are slowing down interest in the leading memecoin. 

DOGE faces ongoing downside pressure Copy link to section

The DOGE/USD 4-hour chart is bearish and efficient as Dogecoin has failed to overcome the $0.145 resistance level over the past few days.

At press time, DOGE is trading at $0.1361, after falling to overcome the 50-day Exponential Moving Average (EMA) at $0.1436. 

The technical indicators suggest that the coin is bearish and could suffer further losses in the near term.

The Moving Average Convergence Divergence (MACD) indicator on the 4-hour chart is below the neutral zone, suggesting a bearish trend. 

The Relative Strength Index stands at 40 below the neutral zone, adding further confluence to the bearish narrative. 

If the selloff continues, DOGE could drop below the $0.1276 support level, turning it into a near-term resistance.

#DOGE Descending Channel Breakout Imminent👨‍💻 Dogecoin is poised to break out from the descending channel formation on the daily chart💁‍♂️ Price action above the MA 50 indicates a potential reversal from a prolonged downtrend structure🔍 Upside targets: 🎯 $0.153 🎯 $0.182 🎯

An extended bearish trend could see DOGE retest the $0.116 level once again. 

However, if buyers defend this level, DOGE could embark on a recovery and hit the $0.15 psychological level over the next few days.
2026-01-12 13:09 2mo ago
2026-01-12 07:26 2mo ago
Monero Is Copying Silver's 150% Breakout Pattern—Here's What Happens Next cryptonews
XMR
Monero (CRYPTO: XMR) surged to a new all-time high of $579 Monday, rising over 20% in 24 hours as veteran trader Peter Brandt identified XMR forming a pattern similar to silver’s classic inverse head-and-shoulders that preceded a 150% rally.

The Silver Pattern Behind XMR’s BreakoutBrandt’s silver chart shows a multi-year base of consolidation before breaking through resistance and accelerating along an ascending trendline. 

XMR Monthly Chart Dynamics By TradingView

Monero’s monthly chart shows a similar structure since its 2021-2022 peak around $450-$500.

After prolonged consolidation in the $150-$200 range through 2023-2024, XMR broke back above major resistance levels around $400 in late 2025 and early 2026. 

If Monero mimics silver’s pattern, the current breakout above $400 could mark the beginning of a larger impulse move toward $700-$1,000+ as it rides the ascending channel higher

The key will be whether XMR holds above the breakout zone around $600 and confirms the pattern, just like silver did.

Dubai Ban Paradoxically Validates Privacy ValueDubai’s financial regulator, the Dubai Financial Services Authority (DFSA), banned privacy tokens from use across the Dubai International Financial Centre (DIFC) on Sunday, citing anti-money laundering and sanctions compliance risks.

Elizabeth Wallace, associate director for policy and legal at DFSA, said privacy tokens have features to hide and anonymize transaction history and holders, making it nearly impossible for firms to comply with Financial Action Task Force requirements.

The prohibition applies broadly across trading, promotion, fund activity, and derivatives in or from the DIFC. 

The DFSA rules also prohibit regulated firms from using mixers, tumblers, or obfuscation tools that hide transaction details.

The ban ironically strengthens Monero’s appeal: if regulators must ban it because they can’t track transactions, it proves the privacy technology actually works. 

This creates demand from users who want financial privacy that governments can’t penetrate.

Privacy Token Rally Outperforms BitcoinMonero’s breakout decisively outperformed both Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH). 

Moreover, Zcash (CRYPTO: ZEC) fell about 25% over the past week to around $402 after the entire Electric Coin Company development team resigned January 7 following a governance dispute, shifting trader focus to Monero as the dominant privacy play.

Analysts at 10x Research also wrote that Monero benefited from renewed focus on privacy and anticipation around upcoming protocol upgrades, which reignited demand despite persistent regulatory risks.

Additionally, market maker Flowdesk said the rally reflected traders being caught offside after the holiday period, with suppressed funding rates through December setting the stage for short covering when liquidity returned.

The technical breakout combined with regulatory validation of Monero’s privacy features could drive the $700-$1,000+ targets if the silver pattern holds. 

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
2026-01-12 13:09 2mo ago
2026-01-12 07:30 2mo ago
Quantum computing threatens the $2 trillion Bitcoin network. BTQ Technologies says it has a defense. cryptonews
BTC
Post-quantum cryptography specialist BTQ Technologies has introduced ‘Bitcoin Quantum,' a permissionless fork and testnet of the largest cryptocurrency.
2026-01-12 13:09 2mo ago
2026-01-12 07:30 2mo ago
ETFs Recap: Bitcoin and Ether Bleed as Solana and XRP Hold Firm cryptonews
BTC ETH SOL XRP
The first full trading week of January delivered a sharp divergence across crypto ETFs, with bitcoin and ether ending in net outflows while solana and XRP quietly extended their momentum. Fund-level flows revealed shifting investor preferences as risk appetite narrowed rather than disappeared.
2026-01-12 13:09 2mo ago
2026-01-12 07:30 2mo ago
Ethereum Needs Better Decentralized Stablecoins, Buterin Says cryptonews
ETH
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Ethereum needs “better decentralized stablecoins,” Vitalik Buterin said this weekend, arguing that the next iteration has to solve three design constraints that today’s models keep skirting. His comments landed alongside a broader claim from MetaLeX founder Gabriel Shapiro that Ethereum is increasingly a “contrarian bet” versus what much of the venture-backed crypto stack is optimizing for.

Shapiro framed the split in ideological terms, saying it is “increasingly obvious that Ethereum is a contrarian bet against most of what crypto VCs are betting on,” listing “gambling,” “CeDeFi,” “custodial stablecoins,” and “’neo-banks’” as the center of gravity. By contrast, he argued, “Ethereum is tripling down on disrupting power to enable sovereign individuals.”

Why Ethereum Lacks A Decentralized Stablecoin Buterin’s stablecoin critique starts with what to stabilize against. He said “tracking USD is fine short term,” but suggested that a long-horizon version of “nation state resilience” points to something that is not dependent on a single fiat “price ticker.”

“Tracking USD is fine short term, but imo part of the vision of nation state resilience should be independence even from that price ticker,” Buterin wrote. “On a 20 year timeline, well, what if it hyperinflates, even moderately?”
That premise shifts the stablecoin problem from simply maintaining a peg to building a reference index that can plausibly survive macro regime changes. In Buterin’s framing, that is “problem” one: identifying an index “better than USD price,” at least as a north star even if USD tracking remains expedient near term.

The second issue is governance and oracle security. Buterin argued that a decentralized oracle must be “not capturable with a large pool of money,” or the system is forced into unattractive tradeoffs that ultimately land on users.

“If you don’t have (2), then you have to ensure cost of capture > protocol token market cap, which in turn implies protocol value extraction > discount rate, which is quite bad for users,” he wrote. “This is a big part of why I constantly rail against financialized governance btw: it inherently has no defense/offense asymmetry, and so high levels of extraction are the only way to be stable.”

He tied that to a longer-running discomfort with token-holder-driven control structures that resemble markets for influence. In his view, “financialized governance” trends toward systems that must continuously extract value to defend themselves, rather than relying on a structural advantage that makes attacks meaningfully harder than normal operation.

The third problem is mechanical: staking yield competes with decentralized stablecoins for capital. If stablecoin users and collateral providers are implicitly giving up a few percentage points of return relative to staking ETH, Buterin called that “quite bad,” and suggested it becomes a persistent headwind unless the ecosystem changes how yield, collateral, and risk interact.

He laid out what he described as a map of the “solution space,” while stressing it was “not endorsement.” Those paths ranged from compressing staking yield toward “hobbyist level,” to creating a staking category with similar returns but without comparable slashing risk, to making “slashable staking compatible with usability as collateral.”

Buterin also sharpened what “slashing risk” actually means in this context. “If you’re going to try to reason through this in detail,” he wrote, “remember that the ‘slashing risk’ to guard against is both self-contradiction, and being on the wrong side of an inactivity leak, ie. engaging in a 51% censorship attack. In general, we think too much about the former and not enough about the latter.”

The constraint bleeds into liquidation dynamics as well. He noted that a stablecoin “cannot be secured with a fixed amount of ETH collateral,” because large drawdowns require active rebalancing, and any design that sources yield from staking must reckon with how that yield turns off or changes during stress.

At press time, ETH traded at $3,118.

ETH remains between the 0.5 and 0.618 Fib, 1-week chart | Source: ETHUSDT on TradingView.com Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.
2026-01-12 13:09 2mo ago
2026-01-12 07:36 2mo ago
Ethereum (ETH) Nearing Decision Point After 2 Months of Chop cryptonews
ETH
Ethereum trades around $3,140 after 2 months in range; analysts watch for breakout above $3,350 with targets set near $4K–$7K.

Ethereum (ETH) has been moving sideways over the past two months and has been trading in a range of about $2,600 to $3,350. The asset is stuck without any definite trend, and analysts are on the lookout for a breakout that will give an indication of the next action.

ETH is priced at around $3,140 at press time, showing a 1% gain in the last 24 hours and a slight loss over the past week.

Ethereum Holds Range as Traders Watch for Break ETH has failed to break out of its trading range since late 2025. Analyst Daan Crypto Trades noted that the price action has stayed choppy, saying,

“Still patiently waiting for either of these levels to be broken.”

Resistance remains near $3,350, with support just above $2,630. Despite a few attempts to rally, ETH is still below key moving averages. The Daily 200 EMA is near $3,340, and the Daily 200 MA is higher, around $3,630. Until ETH can close above these levels, the broader trend remains uncertain.

In addition, analyst Michaël van de Poppe commented that ETH is holding above an important resistance zone, which could now act as support.

“The likelihood towards new monthly highs has significantly increased,” he said.

ETH is also following an upward trendline from its December lows, showing a steady structure on lower timeframes. The next upside zone sits close to $3,800.

Meanwhile, the asset faces short-term liquidity clusters, both above and below current levels. Analyst Ted pointed out, “There are large short liquidations from the $3,150–$3,250 level” and added, “There’s a liquidity cluster around the $3,000–$3,050 level.” The price may move through both in the coming days.

You may also like: Bitcoin’s 2026 Rally Has Legs – But Only If These Risks Fade Ethereum Topped $3,250 in Recovery as BitMine Stakes Over $2B ETH Ethereum Suffered Worst Year Since 2018: 9 Red Months in 2025 Futures Activity Returns to Pre-Crash Levels Futures open interest on ETH has recovered fully from the October crash and now sits around 5.07 million contracts, according to KAY. This level matches the peak seen before the market drop, yet the spot price remains nearly 40% below its previous high ($4,950).

$ETH open interest is now back above October 10th crash level.

Meanwhile, prices are still down almost 40%.

No matter what happens, people never learn in crypto. pic.twitter.com/PfC6PVOPrD

— K A Y (@kay_drake_) January 12, 2026

The gap between rising open interest and flat price suggests growing positioning by traders. However, a lack of upward price confirmation may point to risk if support fails.

Interestingly, ETH’s trend against Bitcoin (BTC) has also started to shift. Van de Poppe noted that ETH has been outperforming since April 2025, calling it “an Ethereum market,” similar to 2019. Structure remains intact for now.

As previously reported, Ethereum continues to hold above $3,000 while forming a Wyckoff structure. An established break above $4,000 may open the way to levels of between $5,000 and $7,000.

Tags:
2026-01-12 13:09 2mo ago
2026-01-12 07:37 2mo ago
XRP, Solana funds buck trend as crypto ETPs shed $454M cryptonews
SOL XRP
Bitcoin and Ethereum investment products reversed course last week as Fed rate cut hopes faded. Key Takeaways Crypto exchange-traded products experienced $454 million in outflows last week. The outflows nearly counteracted the $1.5 billion inflows recorded earlier in the year, marking a significant change in market sentiment. Funds tied to XRP and Solana saw strong inflows last week despite a wave of outflows across crypto exchange-traded products, according to a new report from CoinShares.

Bitcoin led the weekly outflows totaling approximately $405 million, followed by Ethereum with $116 million, reversing much of the $1.5 billion in early-year inflows.

In contrast, XRP funds drew in $46 million, while Solana products attracted around $33 million. Sui and Chainlink also closed out the week with minor inflows.

Among providers, Grayscale and Fidelity accounted for the bulk of weekly redemptions, while iShares and ProFunds attracted inflows. Total assets under management stood at $182 billion as of January 9.

Divergence in investor sentiment was clear, as US funds recorded the biggest outflows while Germany, Canada, and Switzerland drew inflows.

Investor outflows from digital asset products last week reflect waning optimism over a March Fed rate cut following recent macro data, as noted by CoinShares analysts.

Markets are pricing in only a 27% chance of a Fed rate cut in March, per the FedWatch tool.

Disclaimer
2026-01-12 13:09 2mo ago
2026-01-12 07:39 2mo ago
Cardano Founder Charles Hoskinson Teases XRP DeFi Revolution cryptonews
ADA XRP
Cardano Founder Charles Hoskinson has confirmed that XRP DeFi is on the way.

Brian Njuguna2 min read

12 January 2026, 12:39 PM

Source: ShutterstockCardano’s Midnight to Bring Private DeFi to XRP — Unlocking $100B in Idle AssetsIn a high-profile Scott Melker podcast interview, Cardano founder Charles Hoskinson confirmed that XRP-focused DeFi is on the way, with Cardano’s privacy-driven Midnight chain set to enable private smart contracts for XRPL assets.

According to Hoskinson, the concept revolves around wrapping XRP on Midnight, Cardano’s upcoming sidechain designed for confidential computation and data protection. 

Once wrapped, XRP could be used across a range of DeFi applications, including lending, borrowing, and yield farming, use cases that have historically been limited or unavailable to the XRPL ecosystem due to its lack of native smart contract functionality.

Well, the strategic significance of the proposal lies in the sheer scale of dormant capital it seeks to activate. With over $100 billion worth of XRP held largely idle, Hoskinson argues that enabling DeFi rails for these assets could represent one of the largest untapped liquidity pools in crypto.

By bridging XRP into a smart contract–capable and privacy-preserving environment, Midnight could allow institutions and retail users alike to deploy capital efficiently without compromising compliance or confidentiality.

Privacy sits at the core of the strategy. Midnight enables selective disclosure, allowing users and institutions to satisfy regulatory requirements while preserving on-chain confidentiality. 

This balance makes Midnight especially appealing to enterprise players wary of fully transparent DeFi. According to Hoskinson, it positions Cardano and Midnight as a neutral settlement and computation layer, complementing the XRP Ledger (XRPL) rather than competing with it.

The announcement builds on Hoskinson’s outreach to the XRP community in December, when he publicly invited XRPL developers and stakeholders to collaborate at a DeFi-focused summit hosted at the University of Edinburgh. That initiative signaled a shift toward cross-ecosystem cooperation, emphasizing interoperability over tribalism in blockchain development.

If executed successfully, the XRP–Midnight integration could mark a major inflection point for both ecosystems. For XRP holders, it opens the door to yield-generating opportunities long available on other chains. For Cardano, it strengthens its narrative as an infrastructure provider capable of supporting multiple networks through advanced privacy and compliance tooling.

ConclusionHoskinson’s confirmation marks a potential inflection point for XRP and cross-chain DeFi. By pairing XRP’s deep liquidity with Midnight’s privacy-preserving smart contracts, the initiative could activate billions in idle capital while resolving long-standing compliance and confidentiality concerns. 

If successfully implemented, this collaboration would not only expand XRP’s real-world utility but also establish a new benchmark for interoperable, enterprise-ready DeFi across major blockchain ecosystems.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Brian Njuguna is a seasoned crypto journalist at Coinpaper, specializing in blockchain innovation, market trends, and regulatory developments. With a background in economics and years of experience covering the digital asset space, Brian delivers sharp, data-driven insights that cut through the hype. His reporting bridges global crypto narratives with emerging market perspectives, making complex topics accessible to a wide audience.

Read more about

Latest Cryptocurrencies News TodayXRP (Ripple) News
2026-01-12 13:09 2mo ago
2026-01-12 07:45 2mo ago
Ethereum Rainbow Chart predicts ETH price for January 31, 2026 cryptonews
ETH
Ethereum’s (ETH) long-term valuation model, the Rainbow Chart, points to a broad but structured price range by January 31, 2026, based on its historical growth curve and logarithmic trend bands.

Notably, the chart maps Ethereum’s price action across color-coded valuation zones designed to capture market psychology rather than provide precise price forecasts.

Indeed, the model’s outlook comes as Ethereum trades just above the $3,000 support level. As of press time, the asset was valued at $3,102, down less than 0.1% in the past 24 hours, while on the weekly timeline, ETH was down over 2%.

ETH seven-day price chart. Source: Finbold This price range places the second-ranked cryptocurrency by market cap in the lower-middle portion of the Rainbow Chart, a region typically associated with accumulation and undervaluation narratives.

From this starting point, the model outlines multiple valuation bands that ETH could occupy by the end of January 2026, depending on market momentum, adoption trends, and broader macro conditions.

Ethereum price prediction At the base of the model is the ‘Fire Sale’ band, historically associated with extreme pessimism and capitulation, which for January 31, 2026, spans roughly $993 to $1,339 and would imply a sharp breakdown from current levels. Just above it, the ‘Undervalued’ band ranges from about $1,339 to $1,842, indicating Ethereum trading below its long-term trend as patient investors begin to re-enter.

Ethereum rainbow price chart. Source: BlockchainCenter The ‘Accumulate’ band projects a range of about $1,842 to $2,576, signaling improving sentiment with continued caution typical of early recovery phases. Above it, the ‘Still Cheap’ band spans roughly $2,576 to $3,650, pointing to modest gains from current levels and a market that recognizes Ethereum’s value without excess optimism.

The ‘Steady…’ band, ranging from about $3,650 to $5,250, reflects balanced conditions where price growth closely tracks Ethereum’s long-term adoption trend, suggesting a mature uptrend.

Above that, the orange ‘HODL!’ band spans roughly $5,250 to $7,612, reflecting strong bullish conviction driven by long-term holders and limited selling pressure. The darker orange ‘Is This 

Ethereum bullish phase  The Flippening?’ band follows at about $7,612 to $11,050, signaling heightened optimism and speculative interest around Ethereum’s growing market influence.

Near the top, the red-orange ‘But have we ‘earned’ it?’ band ranges from approximately $11,050 to $15,776, indicating stretched valuations and sustainability concerns. The ‘Maximum Bubble Territory’ band caps the model at roughly $15,776 to $22,453 by January 31, 2026, a zone historically linked to euphoric conditions and major corrections.

Given Ethereum’s current price of $3,102, the model implies that remaining within the ‘Still Cheap’ or ‘Steady…’ bands would require moderate appreciation, while a move into the higher orange and red zones would signal a powerful bull cycle.

Featured image via Shutterstock
2026-01-12 13:09 2mo ago
2026-01-12 07:46 2mo ago
BNB slides to $900 as traders look to havens cryptonews
BNB
The token's price action shows signs of indecision, with a tight trading range and fading selling pressure.
2026-01-12 13:09 2mo ago
2026-01-12 07:46 2mo ago
Tether freezes $182 million in USDT stablecoin across five Tron blockchain wallets cryptonews
TRX USDT
The freezes were part of Tether's policy to comply with U.S. Treasury sanctions and were executed in a coordinated manner.
2026-01-12 13:09 2mo ago
2026-01-12 07:49 2mo ago
Ethereum Price Shows Early Strength—Why a Break Above $3,200 Matters for ETH's Next Move cryptonews
ETH
The Ethereum price is attempting to regain bullish momentum after rebounding from the $3,000 support zone, but upside progress remains doubtful. Sellers continue to restrict the recovery below a well-defined resistance range, which has now emerged as a critical threshold for trend continuation. While the rebound reflects underlying demand, technical indicators suggest that clearing this zone may require sustained buying pressure rather than a quick breakout. 

Until ETH decisively secures this range, the probability of a broader rally toward $3,500 remains limited, keeping price action vulnerable to extended consolidation.

Currently, the ETH price is trading within a broad consolidation after a sharp decline from higher levels. Price rebounded from the strong lower support zone, highlighting the strong presence of the bulls who defended the dips. However, the price failed to break above the resistance and remained capped below the range. As a result, the crypto continues to chop around a tight range following a range-bound consolidation. 

Now the question arises whether the ETH price will continue with its sluggish behavior or break above the crucial resistance and eventually rise above the decisive phase.

As seen in the above chart, the ETH price continues to trade within a decisive triangle, holding the ascending and descending trend lines as support & resistance. The structure has historically been bullish, but the technicals now suggest a pullback below $3000 could be mandatory. The Chainkin Money Flow (CMF), which has just risen above 1, is showing a bearish divergence, suggesting the capital is flowing out of the crypto. On the other hand, the MACD is preparing for a bearish crossover, causing a deeper correction for the ETH price. 

However, the range between $3,029 and  $3,070 could act as a strong base, helping the token to trigger a rebound. In case of a failure, the Ethereum (ETH) price may not only plunge below the range but also break the triangle and range lower. In such a case, a drop close to $2800 could be imminent. On the other hand, a successful rise above $3200 could erase the bearish possibility and pave the way for a continued upswing, probably beyond $3500. 

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.
2026-01-12 13:09 2mo ago
2026-01-12 07:50 2mo ago
SHIB Burns Collapse 94% Despite Recent Ultra-Bullish Message From SHIB Team cryptonews
SHIB
Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Despite harsh market turbulence, Shiba Inu remains a major popular meme cryptocurrency among crypto users. A loyal community continues to regularly reduce the circulating SHIB supply.

However, the chart shows that over the past day, the SHIB burn rate has greatly collapsed, even despite the recent bullish message issued by top Shiba Inu team member, Lucie.

SHIB burn rate crashesAccording to the figures shared by Shibburn on-chain data tracker, over the past day, SHIB burns have taken a big dent and collapsed by more than 94%. Overall, only 224,644 SHIB were burned, which is a tiny amount compared to the previous day.

HOT Stories

On Saturday, the portal registered three burn transactions, surpassing three million meme coins: 2,943,898 SHIB; 616,350 SHIB and 395,729 SHIB.

In total, the joint efforts of the Shiba Inu community have already helped to remove a total of 410,754,198,122,381 SHIB from the circulating supply. Additionally, 3,856,265,086,248 SHIB coins have been staked, which means they are also out of circulation — but not permanently.

You Might Also Like

SHIB exec speaks on SOU to compensate Shibarium usersIn a recently published tweet, SHIB's top executive, Lucie, who is in charge of social media marketing, spoke about the SOU recovery framework. SOU stands for “SHIB owes you,” and it was launched after the Shibarium hack that took place at the end of 2025: the Plasma Bridge exploit. That unfortunate event affected many Shibarium users, and now the SHIB team is doing their best to reimburse them for that.

Lucie revealed that the SOU recovery framework consists of two layers — one is official, and the other one is made for the SHIB community. The official layer is “SOU NFTs on Ethereum,” and it comes from the Shiba Inu team itself. Lucie stated that this is the “accounting layer,” and it was made not for raising money but for tracking the debt to Shibarium users.

The second layer is a “community recovery layer” and, according to the tweet, it is “a liquidity and fee generation mechanism.” Lucie also shared the exact role this project will be playing in the recovery mechanism: “Its role is to create volume, generate fees, route part of that activity into recovery and ecosystem support.”

SOU Recovery Framework
Official Ethereum Claims and Community BSC Funding

Shib Owes You has two layers.

One is official.
One is community powered.

They do different jobs.

1) Official layer

SOU NFTs on Ethereum

This is the Shiba Inu team system.

These NFTs represent what… pic.twitter.com/nEkeWbeXGh

— 𝐋𝐔𝐂𝐈𝐄 (@LucieSHIB) January 10, 2026 Lucie concluded her tweet with a disclaimer that this is solely her vision and not the official message of the SHIB team.
2026-01-12 13:09 2mo ago
2026-01-12 07:53 2mo ago
BTC Rejection at $95K Can Spell Further Trouble Ahead (Bitcoin Price Analysis) cryptonews
BTC
Bitcoin has entered a consolidation phase after a sharp sell-off in November last year. While the broader trend remains under pressure, short-term price action is compressing within a tightening structure. With flashing signs of weakened demand from U.S. spot buyers and prices stuck below major moving averages, BTC traders need to keep a close eye on support levels and whether buyers can regain momentum from here.

Bitcoin Price Analysis: The Daily Chart On the daily timeframe, BTC is forming a clear rising wedge pattern after its recent rebound stalled just below the $95K resistance zone. The pattern is getting tighter, with both the higher and lower boundaries being tested multiple times, hinting that a breakout is nearing. Both the 100-day and 200-day moving averages also remain above the current price, acting as dynamic resistance near $98K and $105K marks, respectively.

Bitcoin’s price was recently rejected from $95K supply zone, which coincides with the wedge pattern’s upper boundary. The RSI has also cooled off from overbought levels and is now hovering around 50, indicating a lack of bullish momentum but also room for a potential push if buyers return.

In this situation, if the wedge breaks to the downside, the next key support lies around the $80K area. A bullish breakout, on the other hand, would need to reclaim $95K and push above the mentioned moving averages before it can be taken as a serious sign of a new rally.

BTC/USDT 4-Hour Chart Zooming into the 4-hour chart, the same rising wedge structure is more visible. The price continues to respect the rising trendline from November’s low, but multiple attempts to break above $95K have failed.

Momentum on lower timeframes is choppy, with no clear follow-through from either side. Buyers defended the mid-range and the rising trendline several times, but the lack of strength near resistance is concerning.

A breakdown below the lower boundary near $88K would likely trigger a retest of the high-volume node near $86K and possibly push BTC toward the major green demand zone around $80K. On the flip side, if buyers manage to reclaim the $92K high and break above the key $95K resistance zone, an aggressive move toward the critical $100K level could be expected.

Sentiment Analysis The Coinbase Premium Index, which tracks the price difference between Coinbase and global exchanges, has been printing significant negative values and still remains in the red. Historically, strong positive premiums have accompanied major uptrends, especially when driven by U.S.-based spot buyers.

The current negative premium suggests reduced demand from U.S. institutional and retail players, a potential warning sign that the recent bounce might not be sustainable. This metric has often preceded deeper pullbacks during correction phases. Until the premium shifts back to positive territory, any bullish move should be treated with caution.

Tags:
2026-01-12 13:09 2mo ago
2026-01-12 07:57 2mo ago
XRP Shines as Crypto Funds Bag $454 Million Outflow cryptonews
XRP
Key NotesXRP posted strong inflows while most crypto funds recorded heavy weekly outflows.Bitcoin and Ethereum led losses as investors reacted to delayed Fed rate cut hopes.US markets drove selling pressure, while Europe and Canada showed steady demand. XRP XRP $2.05 24h volatility: 2.6% Market cap: $124.23 B Vol. 24h: $3.28 B stayed in positive territory even as digital asset funds posted $454 million in weekly outflows. This happened as investors pulled back from Bitcoin BTC $90 656 24h volatility: 0.2% Market cap: $1.81 T Vol. 24h: $35.53 B and Ethereum ETH $3 114 24h volatility: 0.1% Market cap: $375.77 B Vol. 24h: $17.66 B while favoring select altcoins amid rising concerns over delayed US rate cuts.

XRP Attracts Inflows as Market Turns Defensive XRP emerged as one of the few bright spots in a difficult week for crypto funds.

While the broader market saw heavy withdrawals, XRP recorded inflows of $45.8 million, according to the latest CoinShares data. This came as investors reduced exposure to major assets, especially Bitcoin and Ethereum, which faced sharp outflows.

The wider digital asset market recorded $454 million in total outflows for the week. This extended a four-day selling streak that erased most of the $1.5 billion inflows seen at the start of the year.

Still, market sentiment weakened after fresh economic data lowered expectations for a US Federal Reserve rate cut in March.

Bitcoin carried the largest share of losses, with $404.7 million leaving BTC-linked products. Ethereum followed with $116.1 million in outflows. Multi-asset products also saw withdrawals of $20.8 million, showing a cautious stance across diversified strategies.

In contrast, XRP continued to draw steady interest. Solana and Sui also posted inflows of $32.8 million and $7.6 million, signaling selective risk-taking rather than a full market exit.

Despite this positive news, XRP had a rough first week of 2026. Coinspeaker disclosed that US-listed spot XRP ETFs recorded their first net outflow of $40.7 million on Jan. 7. This ended a 6-7 week run of steady inflows as the wider crypto ETF market weakened.

In the same week, XRP price fell 5% to $2.27 after WisdomTree withdrew its ETF filing, even as US spot XRP ETFs saw continued inflows.

As of writing, XRP is trading at $2.03, down 2.42% per CoinMarketCap data.

XRP Gains as US Leads Regional Outflows Regional data showed a clear split. The United States recorded $568.9 million in outflows, making it the main driver of weekly losses. Investor sentiment in the US turned negative as bond yields rose and rate cut hopes faded.

Outside the US, several markets remained firm. Germany led inflows with $58.9 million, followed by Canada at $24.5 million and Switzerland at $21 million. These inflows helped offset some global pressure and supported assets like XRP.

Interestingly, XRP stood out again in this regional mix, benefiting from demand outside the US. While overall market confidence weakened, XRP maintained its appeal, reflecting a focused shift rather than broad selling.

In a related XRP update, Coinspeaker noted that Ripple has abandoned its IPO plans, with President Monica Long saying public funding is not needed for growth.

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Cryptocurrency News, News

Benjamin Godfrey is a blockchain enthusiast and journalist who relishes writing about the real life applications of blockchain technology and innovations to drive general acceptance and worldwide integration of the emerging technology. His desire to educate people about cryptocurrencies inspires his contributions to renowned blockchain media and sites.

Godfrey Benjamin on X
2026-01-12 13:09 2mo ago
2026-01-12 07:57 2mo ago
XRP Ledger Set to Unlock Tokenized Gold Revolution cryptonews
PAXG XAUT XRP
Tokenized Gold Eyes XRP Ledger as Demand for Digital Assets GrowsAs highlighted by leading on-chain metrics provider Coin Bureau, tokenized gold may soon arrive on the XRP Ledger, sparking excitement across the crypto community. 

Advocates point to XRPL’s robust infrastructure, high transaction throughput, and low fees as ideal for hosting tokenized precious metals.

Community voices are increasingly bullish on the prospect. Phil Kwok of EasyA declared, “Tokenized gold is coming to the XRPL,” signaling confidence that the ledger is poised to handle tokenized assets. 

Validators such as Vet have also emphasized the strong technical fit, noting that XRPL’s immutable ledger and decentralized validation process could provide the trust and transparency required for asset-backed tokens.

Tokenized gold and silver represent a growing sector within digital finance, allowing investors to hold real-world assets in a digital form. By leveraging blockchain technology, these tokens can combine the stability of traditional precious metals with the efficiency, accessibility, and programmability of crypto. 

On XRPL, this could open avenues for instant settlement, automated trading, and even integration into decentralized finance (DeFi) protocols.

XRP Ledger’s appeal for tokenized metals goes beyond tech. Its mature ecosystem of exchanges, wallets, and payment providers could accelerate adoption, offering investors lower costs, easier access, and secure, transparent ownership. Ripple’s talks with AWS to leverage Amazon Bedrock may further revolutionize how the network scales and manages operations.

Although still in early discussions, tokenized gold on XRPL is seen as part of a growing trend linking traditional finance with digital assets. Beyond serving as an investment vehicle, it could provide institutional participants a way to access crypto markets while mitigating volatility through exposure to physical metals.

If realized, this development would showcase XRPL’s versatility, reinforcing its role as a platform capable of supporting both mainstream financial instruments and innovative blockchain solutions. With its speed, scalability, and security, XRPL may be poised to bring gold and silver tokenization to market sooner than anticipated.

ConclusionTokenized gold on the XRP Ledger could transform how traditional finance meets blockchain, giving investors a secure, efficient, and accessible way to trade precious metals. Leveraging XRPL’s speed, scalability, and transparency, the network is poised to set a new standard for digital representation and exchange of physical assets.
2026-01-12 13:09 2mo ago
2026-01-12 07:59 2mo ago
Ripple Price Analysis: XRP Defies Geopolitical Tension but Breakdown Risks Still Linger cryptonews
XRP
XRP is showing signs of weakness after its recent breakout, while the broader market sentiment remains cautiously optimistic. Despite geopolitical tensions rising in the Middle East and Asia, Bitcoin and crypto markets are holding much better than expected, and XRP is no exception.

XRP Price Analysis: The USDT Pair XRP recently surged into a major resistance area around $2.40, just below the key 200-day moving average. The asset was quickly rejected, broken back below the 100-day moving average (located around $2.20), and is now pulling back toward the $2.00 support range. This zone also aligns with the mid-range of the recent move, providing a short-term support cushion.

Yet, momentum has slowed, as seen in the RSI rolling over from the overbought zone and is now on the verge of dropping below 50. A daily close below $2.00 could expose XRP to further downside toward the recent major low at $1.80. On the upside, reclaiming the 100-day moving average and closing above the $2.40 supply zone would reopen the door toward the 200-day moving average and even the significant $3 level as potential targets for the upcoming months.

The BTC Pair On the XRPBTC pair’s daily timeframe, Ripple’s token briefly broke above both the 100-day and 200-day moving averages, rallying from 2,100 sats to just under 2,600 sats before experiencing a decisive rejection. The price is now trading around 2,250 sats and back below the 200-day moving average (located around 2,400 sats). The 100-day moving average is currently holding the price near the 2,250 level.

As long as the 2,200–2,250 sats area holds, buyers still have a chance to build a higher low structure. Losing that zone would likely send XRP back toward the 2,000 sats demand zone. Meanwhile, a bounce and reclaim of the 2,400 sats level could start a fresh leg toward the 2,700–2,800 sats range again. However, until this scenario happens, XRP remains weak and is likely to underperform against BTC.

Tags:
2026-01-12 13:09 2mo ago
2026-01-12 08:00 2mo ago
Here's what needs to happen for XRP to reach $3 by the end of January cryptonews
XRP
Journalist

Posted: January 12, 2026

Ripple [XRP] has shed 14% in under six days after a feverishly bullish start to January, where it rallied 32.3% in five days. This rally was in a retracement phase, which has bulls asking – can XRP reach $3 by the end of January?

It was not an impossible ask. A recent AMBCrypto report highlighted how whale accumulation and reduced selling pressure from profit-taking meant the bulls were still in control.

If the $2 level remains in buyers’ control, the $3 target would be more likely to be achieved.

XRP: Long-term weakness or growing bullish intent?

Source: XRP/USDT on TradingView

The 1-week chart showed that XRP has gravitated back to the $1.86-$2.22 demand zone that the bulls have defended since December 2024.  Whale accumulation has picked up in recent months, which bodes well for bulls.

Arguing the bearish case for XRP The past week’s rejection from $2.40 was not pretty on the weekly XRP chart. The long wick to the upside represented bulls getting beaten back by the dominant bears.

This did not bode well for a move toward $3 later this month. The RSI was unable to climb back above neutral 50 to signal a momentum shift, and the OBV was also near the December 2024 lows.

Source: XRP/USDT on TradingView

XRP has a bullish structure, but its OBV remained in a bearish spiral. This might not be good enough to assure investors of a strong January performance.

A continued descent below $1.85-$1.90 would put severe stress on the bulls.

Source: TOTAL on TradingView

Moreover, the total market cap has slipped below a multi-year uptrend. At the time of writing, the former trendline support was being retested as resistance.

This was another signal that the recent altcoin momentum to start the year was a temporary relief rally and not a sustainable uptrend.

For XRP to resume its rally, Bitcoin [BTC] needs to climb back above $94.5k. It needs to keep its momentum going to smash aside the $100k psychological resistance as well.

This would turn the market sentiment around and drive fresh capital inflows. Investors should be prepared for XRP to be bearish in the coming weeks, based on the evidence at hand.

Final Thoughts The retest of the weekly demand zone and positive on-chain metrics suggested bullish potential. A closer look at the 1-day chart and the total crypto market cap showed that XRP bulls could be headed for trouble if demand doesn’t step in.

Akashnath S is a Senior Journalist and Technical Analysis expert at AMBCrypto. He specializes in dissecting price action, identifying key market trends through advanced chart patterns, and forecasting both short-term and long-term asset trajectories. His distinct analytical method is grounded in his academic training as a Chemical Engineer. This background provides him with a systematic, process-oriented approach to market data, enabling him to analyze the complex dynamics of financial markets with precision and objectivity. Having actively covered the cryptocurrency space since the landmark 2017 market cycle, Akashnath possesses years of experience navigating both bull and bear markets. This seasoned perspective is critical to his insightful reporting on market volatility and evolution. As an active market participant, Akashnath enhances his analysis with crucial, hands-on experience. This practical application of his technical skills ensures his insights are not merely theoretical, but are also relevant and actionable for an audience looking to understand and navigate trading opportunities. He is dedicated to educating readers on the nuances of technical analysis, empowering them with the knowledge to make more informed financial decisions.
2026-01-12 13:09 2mo ago
2026-01-12 08:01 2mo ago
Bitcoin Core expands trusted maintainer set with sixth keyholder cryptonews
BTC
Bitcoin Core adds sixth trusted maintainer as ‘TheCharlatan’ gains commit key.

Summary

Bitcoin Core added pseudonymous developer TheCharlatan as the sixth Trusted Key holder with direct commit access to the master branch.​ The promotion follows strong backing from Core contributors and reflects ongoing efforts to decentralize control that began after Satoshi’s handover to Gavin Andresen and later Wladimir van der Laan.​ TheCharlatan focuses on reproducible builds and validation logic, extending prior work to separate validating from non-validating code in Bitcoin’s kernel library. Bitcoin Core maintainers have expanded the number of developers holding Trusted Keys with commit power to the master branch of the Bitcoin Core software for the first time since May 2023, according to community records.

Bitcoin Core contributor developments On January 8, 2026, a pseudonymous developer known as TheCharlatan, also referred to as “sedited,” became the sixth keyholder, joining Marco Falke, Gloria Zhao, Ryan Ofsky, Hennadii Stepanov, and Ava Chow.

The group of Trusted Key holders has evolved over the past decade. Falke gained access in 2016, Samuel Dobson in 2018 before exiting by 2022, Stepanov in 2021, Chow in 2021, Zhao in 2022, and Ofsky in 2023, according to Bitcoin Core development records.

Bitcoin (BTC) developers sign software updates with their PGP keys. The 25 members of the GitHub development community for Bitcoin Core software recognize only these six PGP keys with commit access.

In a group discussion among Core contributors, at least 20 members supported TheCharlatan’s promotion to Trusted Keys status, with no objections recorded. The nomination stated: “He is a reliable reviewer who has worked extensively in critical areas of the codebase, thinks carefully about what we ship to users and developers, and understands the technical consensus process well.”

TheCharlatan, a University of Zurich computer science graduate from South Africa, focuses on reproducibility and Bitcoin Core’s validation logic, according to his development profile. Reproducible builds in software development ensure an independently-verifiable path from source to binary code. TheCharlatan’s work on validation logic extends the efforts of Carl Dong on the Bitcoin Core kernel library to separate validating and non-validating logic required to determine if a given block extends the current best-work chain.

When Bitcoin launched in 2009, only Satoshi Nakamoto possessed commit-level access to the Bitcoin project software. Nakamoto transferred key privileges to Gavin Andresen, who subsequently passed control to Wladimir van der Laan. Van der Laan later led an initiative to decentralize control of commit keys to a group, following legal threats from Craig Wright, who lost multi-year court battles against Core developers over copyright to Bitcoin’s whitepaper. That decentralization effort established the current structure in Core development, where six people serve as Lead Maintainers.
2026-01-12 13:09 2mo ago
2026-01-12 08:04 2mo ago
Satoshi Nakamoto Makes First Bitcoin Transfer 17 Years Ago Today cryptonews
BTC
Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The cryptocurrency community has been reminded of a milestone event in the history of digital transactions. Notably, exactly 17 years ago, on Jan. 12, 2009, the first-ever peer-to-peer (P2P) Bitcoin (BTC) transaction was completed.

First Bitcoin transaction that validated digital cashAs highlighted by CoinGecko on X, Bitcoin's pseudonymous creator, Satoshi Nakamoto, performed the milestone transaction shortly after Bitcoin’s launch. On that historic occasion, Satoshi transferred 10 BTC to renowned cryptographer Hal Finney.

The transaction was significant as it was the first real demonstration that Bitcoin could function as digital cash. Satoshi sent the coin directly without any intermediary, as designed by himself, to Hal Finney over the internet.

17 Years Ago Today: Satoshi Nakamoto made Bitcoin’s first P2P transaction, sending 10 $BTC to Hal Finney.

TXID: f4184fc596403b9d638783cf57adfe4c75c605f6356fbc91338530e9831e9e16 pic.twitter.com/mvrJcGnZNI

— CoinGecko (@coingecko) January 12, 2026 It is worth mentioning that the 10 BTC at the time had no market value, as it was just an experiment to show what is possible in the digital space. Today, that same 10 BTC is valued at $903,700 at the current market value.

The unique identifier for that transaction, "f418…9e16," remains accessible and can still be verified on the Bitcoin blockchain. This emphasizes Bitcoin’s immutability and transparency, confirming the network’s unchanged principle over almost 20 years.

From 10 BTC test transfer to $1.8 trillion assetWithin this time frame, Bitcoin has grown into a $1.8 trillion entity in valuation. This indicates that the coin has not only survived, but it is thriving in the broader financial industry.

You Might Also Like

As a mark of acceptability, the New York Stock Exchange (NYSE) has installed a statue of Satoshi Nakamoto in the U.S. Italian artist Valentina Picozzi sculpted the statue, with the installation prepared as part of the exchange’s first week.

Beyond the U.S., similar statutes of Satoshi have been unveiled in Vietnam, Lugano, Switzerland, Japan and El Salvador.

Meanwhile, YoungHoon Kim, noted for holding the highest IQ scores in the world, has hailed Satoshi Nakamoto as the smartest man in history. This is due to the impact of his creation in the financial space and its catalytic effect in the cryptocurrency sector.
2026-01-12 13:09 2mo ago
2026-01-12 08:05 2mo ago
Shiba Inu (SHIB) Sell-Off Looms: Rising Reserves Could Push Price Lower cryptonews
SHIB
14h05 ▪ 4 min read ▪ by Ifeoluwa O.

Summarize this article with:

Shiba Inu (SHIB) has closed the past five days in negative territory, but a look at price alone doesn’t tell the full story. The token’s distribution remains heavily concentrated on exchanges, and recent activity suggests that holders are preparing to sell rather than accumulate. These conditions can weigh on market sentiment and leave SHIB exposed to further downward movement.

In brief Exchange reserves for SHIB have risen above 82.5 trillion, signaling that holders are preparing to sell. Positive exchange netflows show more tokens moving onto trading platforms than being withdrawn. Rising SHIB Reserves Point to Selling Readiness Shiba Inu’s presence on trading platforms has been increasing, with exchange reserves now exceeding 82.5 trillion SHIB, up from about 81 trillion earlier in the year. At the same time, exchange netflow has turned positive, meaning more tokens are being sent to exchanges than withdrawn. This combination of rising reserves and net inflows suggests that holders are preparing to sell rather than accumulate. 

The shift in behavior coincided with SHIB briefly climbing above $0.000009, near its highest level so far this year, before giving up part of its year-to-date gains, reflecting a market dominated by selling readiness.

SHIB Exchange Netflows Signal Growing Sell Pressure SHIB Traders Pull Back While Whales Stay Active The derivatives market adds another layer to the cautious outlook and reflects broader trends in trader behavior:

Trading volume in SHIB derivatives fell by approximately 14% over the past 24 hours. Open interest also declined by around 2%. The token’s price dropped about 2% during the same period, reflecting fading confidence and limited appetite for leveraged positions. Despite this, some signs of support are visible. Data from Santiment indicates a 111% increase in whale transactions, showing heightened activity among large holders. Additionally, CryptoQuant reports that daily active SHIB addresses have been steadily rising since the start of the year, consistently remaining above 3,000. This demonstrates ongoing on-chain engagement even amid recent price weakness.

Technical Outlook Shows Range-Bound Trading From a technical perspective, Shiba Inu is currently consolidating after months of downward pressure. Following a prolonged downtrend since September, the token showed a brief rebound in the first few days of this year, but the recovery has lacked strong momentum and has not confirmed a trend reversal.

On the daily chart, SHIB trades within a clearly defined rectangular range, showing a temporary balance between buyers and sellers. Price has met resistance near the top of this range, while the middle zone—aligned with the 20-day moving average and middle Bollinger Band—provides support, keeping the market neutral.

SHIB Breaks Downtrend with Resistance Retest in Early 2026 Technical indicators support this cautious view. RSI sits around 58, reflecting modest bullish momentum but no clear dominance. Bollinger Bands remain moderately wide after the recent spike, signaling ongoing volatility rather than low activity.

Unless SHIB breaks decisively above the top of the consolidation range (0.0000095) with strong volume, the most likely scenario is continued sideways movement or a pullback toward the lower boundary of the range (0.0000080). A confirmed breakout would be necessary to shift the market structure and reopen the path for a broader recovery.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Ifeoluwa O.

Ifeoluwa specializes in Web3 writing and marketing, with over 5 years of experience creating insightful and strategic content. Beyond this, he trades crypto and is skilled at conducting technical, fundamental, and on-chain analyses.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 stocknewsapi
AXGN
January 12, 2026 07:00 ET  | Source: Axogen, Inc.

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials.

Preliminary Fourth Quarter and Year-End Key Business Highlights

Fourth quarter 2025 revenue is expected to be approximately $59.9 million, which represents a 21.3% increase over the fourth quarter of 2024, driven by solid performance across the product portfolio.Full-year 2025 revenue is expected to be approximately $225.2 million, which represents a 20.2% increase over the full-year of 2024.Our strong performance reflects improved execution across our commercial strategy: targeting high-potential accounts in Extremities and OMF-Head & Neck, expanding utilization of Axogen’s complete peripheral nerve surgical algorithm across all procedures, and increasing penetration of Resensation® in post-mastectomy breast reconstruction.Fourth quarter and full-year 2025 gross margin is expected to be above 74%.Gross margin is expected to reflect one-time costs of approximately $1.9 million, or 3% and 1% for the fourth quarter and full-year 2025, respectively, related to the U.S. Food and Drug Administration (“FDA”) Biologics License Application (“BLA”) approval of Avance®. It is also expected that 67% of the one-time costs are non-cash and relate to the vesting of certain stock compensation awards containing FDA BLA approval of Avance® milestones.The balance of cash, cash equivalents, restricted cash, and investments on December 31, 2025, is expected to be approximately $45.5 million, representing an increase of approximately $6.0 million over the balance at the end of 2024.On December 3, 2025, FDA approved the BLA for Avance® (acellular nerve allograft-arwx).
“We are delighted with our preliminary fourth quarter and full year 2025 results. Our strong revenue growth and notable BLA milestone achievement during the quarter further validate our strategic plan and market development strategies, and importantly, Axogen’s ability to operationally execute,” said Michael Dale, President and Chief Executive Officer of Axogen. “The approval of Avance® as a biologic therapeutic option for treating peripheral nerve discontinuities combined with our positive momentum across all functions within the business give us confidence that our mission to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care is progressing as planned.”

The results disclosed in this press release are preliminary and unaudited. The Company expects to report full results for the fourth quarter and year ended December 31, 2025, in late February 2026.

About Axogen

Axogen (NASDAQ: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.​

For more information, visit www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “priorities,” “objectives,” “targets,” “intends,” “plan(s),” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our preliminary, unaudited fourth quarter and full 2025 performance, statements related to our mission of making peripheral nerve care standard of care for all patients, statements related to the impact of BLA approval and strategic plan and market development, as well as statements under the subheading “Preliminary Fourth Quarter and Year-End Key Business Highlights.” Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon and product adoption rates, market awareness of our products, the projected TAM for targeted markets and other risks described in our filings with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

Media Contact:

Axogen, Inc.
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call stocknewsapi
GLPI
January 12, 2026 07:00 ET  | Source: Gaming and Leisure Properties, Inc.

WYOMISSING, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) announced today that the Company will release its 2025 fourth quarter financial results after the market close on Thursday, February 19, 2026. The Company will host a conference call at 10:00 a.m. ET on Friday, February 20, 2026.

During the conference call, Peter M. Carlino, Chairman and Chief Executive Officer, and senior management, will review the quarter’s results and performance, discuss recent events and conduct a question-and-answer period.

Webcast:
The conference call will be available in the Investor Relations section of the Company’s website at www.glpropinc.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software. A replay of the call will also be available for 90 days on the Company’s website.

To Participate in the Telephone Conference Call:
Dial in at least five minutes prior to start time.
Domestic: 1-877/407-0784
International: 1-201/689-8560

Conference Call Playback:
Domestic: 1-844/512-2921
International: 1-412/317-6671
Passcode: 13758037
The playback can be accessed through Friday, February 27, 2026.

About Gaming and Leisure Properties
GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties.

Contact:
Gaming and Leisure Properties, Inc.                
Carlo Santarelli, SVP - Corporate Strategy & Investor Relations
610-378-8232
[email protected]

Investor Relations
Joseph Jaffoni, Christin Armacost at JCIR
212-835-8500
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025 stocknewsapi
FWRG
BRADENTON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported certain preliminary operational metrics for the thirteen weeks ended December 28, 2025 (“fourth quarter”) and fiscal year ended December 28, 2025 (“2025”).

“Among our team’s 2025 achievements were a record 64 new system-wide restaurant openings across 23 states as well as posting same restaurant sales growth of +3.6% and positive same restaurant traffic growth,” said Chris Tomasso, First Watch CEO and President. “Our 2024 and 2025 new restaurant classes combined continue to outperform the comparable restaurant base and our underwriting expectations, and our pipeline for 2026 is strong. We remain confident in the continued execution of our long-term strategy and extending our lead in Daytime Dining.”

Sales and Traffic Highlights

 Fourth Quarter 2025
Same-Restaurant Sales Growth+3.1%
 +3.6%
Same-Restaurant Traffic Growth-1.9%
 +0.5%

Restaurant Development

During the fourth quarter, there were 13 new system-wide restaurant openings consisting of 12 company-owned restaurants and one franchise-owned restaurant.

During 2025, there were 64 system-wide new restaurant openings (55 company-owned and nine franchise-owned), and three closures.

At December 28, 2025, First Watch had 633 system-wide restaurants, consisting of 560 company-owned restaurants and 73 franchise-owned restaurants across 32 states.

ICR Conference Participation Today

Chris Tomasso, Chief Executive Officer and President, and Mel Hope, Chief Financial Officer, will host a fireside chat today, Monday, January 12, 2026 at the 28th Annual ICR Conference at the Grande Lakes Orlando. The fireside chat webcast will begin at 11:00 a.m. Eastern Time and will be available at https://investors.firstwatch.com in the News & Events section and will be archived on the site shortly after it has concluded. Management will also host meetings at the conference with institutional investors.

Definitions

The following definitions apply to these terms as used in this release:

Same-restaurant sales growth: the percentage change in year-over-year restaurant sales (excluding gift card breakage) for the comparable restaurant base, which is defined as the number of company-owned First Watch branded restaurants open for 18 months or longer as of the beginning of the fiscal year (“Comparable Restaurant Base”). For the 13 weeks and 52 weeks ended December 28, 2025, there were 381 restaurants in our Comparable Restaurant Base. Measuring our same-restaurant sales growth allows management to evaluate the performance of our existing restaurant base. We believe this measure is useful for investors to provide a consistent comparison of restaurant sales results and trends across periods within our core, established restaurant base, unaffected by results of store openings, closings, and other transitional changes.

Same-restaurant traffic growth: the percentage change in traffic counts as compared to the same period in the prior year using the Comparable Restaurant Base. Measuring our same-restaurant traffic growth allows management to evaluate the performance of our existing restaurant base. We believe this measure is useful for investors because an increase in same-restaurant traffic provides an indicator as to the development of our brand and the effectiveness of our marketing strategy.

System-wide restaurants: the total number of restaurants, including all company-owned and franchise- owned restaurants.

About First Watch

First Watch is the leading Daytime Dining concept serving made-to-order breakfast, brunch and lunch using the freshest ingredients available. Guided by its “Follow the Sun” culinary philosophy, First Watch's chef-driven menu rotates five times a year to feature the highest-quality flavors at their peak, offering elevated executions of classic favorites, fresh juices like the Kale Tonic, and fan favorites such as the Lemon Ricotta Pancakes, Quinoa Power Bowl and signature Million Dollar Bacon. For every kid’s meal served, First Watch proudly donates a portion to organizations and causes making a positive impact in our communities – raising more than $1.7 million to date. A recipient of hundreds of local “Best Breakfast” and “Best Brunch” awards, First Watch was voted 2025’s #1 Best Breakfast by Newsweek’s Readers’ Choice Awards and was also named 2025 and 2024’s #1 Most Loved Workplace® in America by the Best Practice Institute (as seen in The Wall Street Journal), after appearing on the list in 2022 and 2023 as well. With a commitment to quality, hospitality and community, First Watch is redefining Daytime Dining across more than 630 restaurants in 32 states. For more information, visit www.firstwatch.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to any historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “outlook,” “potential,” “project,” “projection,” “plan,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other similar expressions. You should evaluate all forward-looking statements made in this press release in the context of the risks and uncertainties disclosed herein, in our Annual Report on Form 10-K as of and for the year ended December 29, 2024, including under Part I. Item 1A. “Risk Factors” and Part II. Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investors Relations section of the Company’s website at https://investors.firstwatch.com/financial-information/sec-filings. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: our vulnerability to changes in consumer preferences and economic conditions such as inflation and recession; uncertainty regarding the Russia and Ukraine war, war and unrest in the Middle East and the related impact on macroeconomic conditions, including inflation, as a result of such conflicts or other related events; our vulnerability to changes in economic conditions and consumer preferences; our inability to successfully open new restaurants or establish new markets; our inability to effectively manage our growth; potential negative impacts on sales at our and our franchisees’ restaurants as a result of our opening new restaurants; a decline in visitors to any of the retail centers, lifestyle centers, or entertainment centers where our restaurants are located; lower than expected same-restaurant sales growth; unsuccessful marketing programs and limited time new offerings; changes in the cost of food; unprofitability or closure of new restaurants or lower than previously experienced performance in existing restaurants; our inability to compete effectively for customers; unsuccessful financial performance of our franchisees; our limited control over our franchisees’ operations; our inability to maintain good relationships with our franchisees; conflicts of interest with our franchisees; the geographic concentration of our system-wide restaurant base in the southeast portion of the United States; damage to our reputation and negative publicity; our inability or failure to recognize, respond to and effectively manage the accelerated impact of social media; our limited number of suppliers and distributors for several of our frequently used ingredients and shortages or disruptions in the supply or delivery of such ingredients; information technology system failures or breaches of our network security; our failure to comply with federal and state laws and regulations relating to privacy, data protection, advertising and consumer protection, or the expansion of current or the enactment of new laws or regulations relating to privacy, data protection, advertising and consumer protection; our potential liability with our gift cards under the property laws of some states; our failure to enforce and maintain our trademarks and protect our other intellectual property; litigation with respect to intellectual property assets; our dependence on our executive officers and certain other key employees; our inability to identify, hire, train and retain qualified individuals for our workforce; our failure to obtain or to properly verify the employment eligibility of our employees; our failure to maintain our corporate culture as we grow; unionization activities among our employees; employment and labor law proceedings; labor shortages or increased labor costs or health care costs; risks associated with leasing property subject to long-term and non-cancelable leases; risks related to our sale of alcoholic beverages; costly and complex compliance with federal, state and local laws, including trade and tax policies; changes in accounting principles applicable to us; our vulnerability to natural disasters, unusual weather conditions, pandemic outbreaks, political events, war and terrorism; our inability to secure additional capital to support business growth; our level of indebtedness; and failure to comply with covenants under our credit facility.

The forward-looking statements included in this press release are made only as of the date hereof and are expressly qualified in their entirety by these cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. All information presented herein is based on our fiscal calendar. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years and the associated quarters, months and periods of those fiscal years.

Investor Relations Contact:
Steven L. Marotta
941-500-1918
[email protected]

Media Relations Contact:
Jenni Glester
407-864-5823
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Highwoods Announces Investment Activity stocknewsapi
HIW
_____________________________________

Acquires Bloc83 in CBD Raleigh in
Joint Venture with the North Carolina Investment Authority
$21.0M Total Investment (at HIW 10% Share)
492,000 Square Feet, 97% Leased
_____________________________________

Acquires The Terraces in Preston Center BBD in Dallas in
Joint Venture with Granite Properties
$87.4M Total Investment (at HIW 80% Share)
173,000 Square Feet, 98% Leased
_____________________________________

Acquisitions to be Funded Primarily Through
Sales of Non-Core Assets
Expect Leverage-Neutral Rotation of Capital by Mid-2026
_________________________________________

Plan Expected to Strengthen Long-Term Growth Trajectory 
Immediately Accretive to Cash Flows
Neutral to Current FFO Run Rate; Accretive over Long-Term
_________________________________________

RALEIGH, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has acquired Bloc83, a two-building, 492,000 square foot mixed-use asset in CBD Raleigh, in a joint venture with the North Carolina Investment Authority and The Terraces, a 173,000 square foot office building in the Preston Center BBD of Dallas, in a joint venture with Granite Properties.

Ted Klinck, President and CEO, stated, “We are excited to expand our presence in Dallas and Raleigh with the addition of two best-in-class properties at attractive risk-adjusted yields with good long-term growth potential. The acquisition of The Terraces deepens our relationship with our partner in Dallas, Granite, and marks our entry into Preston Center, a BBD we identified for future expansion when we entered Dallas in 2022. Preston Center is the most supply-constrained BBD in the Dallas market with a healthy outlook for long-term rent growth. With in-place rents approximately 30% below market, there is significant NOI upside at The Terraces as leases roll during the next few years. Our Dallas portfolio is now projected to be approximately 7% of our total NOI upon stabilization of our development properties, which would make it our 5th largest market.

“Bloc83 is a property we have followed closely since it was first developed. Located in Raleigh’s CBD and just a few blocks from our corporate headquarters, Bloc83 is an excellent strategic fit within our portfolio. The property is 97% leased, 17% higher than the downtown competitive set. We now own 2.0 million square feet in CBD Raleigh, which gives us flexibility to accommodate the evolving space needs of our existing customers and prospects. Additionally, we have expanded our roster of strategic investment partners with the formation of a new joint venture with the North Carolina Investment Authority.

“Our plan is to effectively match-fund our purchase of these best-in-class assets in the high-growth markets of Dallas and Raleigh by selling a select portfolio of non-core assets or properties where we believe value has been maximized. Importantly, once completed, our plan is expected to be roughly leverage-neutral, accretive to cash flows and neutral to our near-term FFO run-rate, while improving the quality of our portfolio and providing higher growth in cash flows and FFO over time.”

Acquisition of Bloc83
Bloc83 is a 492,000 square foot mixed-use asset that includes two 10-story best-in-class office buildings with 27,000 square feet of ground floor amenity retail located in CBD Raleigh. The building includes a rooftop terrace, customer lounge, fitness center, and interactive sports room with a golf simulator, among other on-site customer amenities. Bloc83, which delivered between 2019 and 2021, was 97% leased on a combined basis at December 31, 2025 with a weighted average lease term of 6.5 years.

The Company initially owns a 10% interest in the joint venture that was formed to acquire Bloc83. The North Carolina Investment Authority, a new strategic investment partner for Highwoods, owns the remaining 90% interest. The Company retains the option to increase its ownership interest to 50%. The joint venture’s total investment (at 100%) is expected to be $210.5 million, which includes $3.3 million of planned near-term building improvements and $0.5 million of transaction costs.

Acquisition of The Terraces
The Terraces is a 12-story best-in-class office building encompassing 173,00 square feet located in the heart of Dallas’ Preston Center, a new BBD for Highwoods. The Terraces, which delivered in 2017, was 98% leased at December 31, 2025 with a weighted average lease term of 7.0 years. Rents are approximately 30% below market, which provides significant long-term upside potential.

The Company owns an 80% interest in the joint venture that was formed to acquire The Terraces. Granite, the Company’s longtime partner in Dallas, owns the remaining 20% interest. The Company also contributed to the joint venture $12.9 million (net of the Company’s 80% interest) of preferred equity. The joint venture’s total investment (at 100%) is expected to be $109.3 million, which includes $2.5 million of planned near-term building improvements and $0.5 million of transaction costs.

2026 NOI Outlook
During 2026, the Company’s combined investment in The Terraces and Bloc83 joint ventures is expected to generate GAAP net operating income of $9.0 million and cash net operating income of $7.5 million. In addition, the Company expects to generate approximately $0.8 million of income during 2026 from its net preferred equity investment in The Terraces joint venture.

Funding Plan
The Company’s plan is to ultimately fund these acquisitions, and the $223.1 million acquisition of 6Hundred at Legacy Union in Charlotte that closed during the fourth quarter of 2025, primarily by accelerating the sale of a select portfolio of non-core assets or properties where we believe value has been maximized. The Company expects to complete this leverage-neutral rotation of capital by mid-2026.

During the fourth quarter of 2025, the Company sold in a series of transactions non-core assets for combined gross proceeds of $65.9 million. The sold assets consist of: (1) a 42-year old office building encompassing 27,000 square feet at Century Center in Atlanta; (2) a 49-year old office building encompassing 57,000 square feet in Tampa’s Westshore BBD; (3) a 2.1-acre surface parking lot in CBD Orlando and a 0.7-acre surface parking lot in CBD Raleigh; (4) a 25-year old office building encompassing 35,000 square feet in the Research Triangle Park submarket of Raleigh; and (5) the Company’s 50% interest in a joint venture that owns three office buildings encompassing 354,000 square feet in the Innsbrook BBD of Richmond. Additionally, the Company expects to close on the sale of three additional non-core buildings for a combined purchase price of $42.2 million in the next 45 days.

Presentation
A presentation highlighting the planned acquisition and planned acceleration of non-core dispositions can be accessed through the link below and in the Investors section of the Company’s website at www.highwoods.com.

About Highwoods
Highwoods Properties, Inc., headquartered in Raleigh, is a publicly-traded (NYSE:HIW), fully-integrated office real estate investment trust (“REIT”) that owns, develops, acquires, leases and manages properties primarily in the best business districts (BBDs) of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond and Tampa. Our vision is to be a leader in the evolution of commercial real estate for the benefit of our customers, our communities and those who invest with us. Our mission is to create environments and experiences that inspire our teammates and our customers to achieve more together. We are in the work-placemaking business and believe that by creating exceptional environments and experiences, we can deliver greater value to our customers, their teammates and, in turn, our shareholders. For more information about Highwoods, please visit our website at www.highwoods.com.

Forward-Looking Statements
Some of the information in this press release may contain forward-looking statements. Such statements include, in particular, statements about our plans, strategies and prospects such as the following: closing of the planned acquisition may not occur on the terms described in this press release or at all; the expected financial and operational results and the related assumptions underlying our expected results; the planned sales of non-core assets and expected pricing and impact with respect to such sales, including the tax impact of such sales; the anticipated total investment, projected leasing activity, estimated replacement cost and expected net operating income of acquired properties and properties to be developed; and expected future leverage of the Company. You can identify forward-looking statements by our use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue” or other similar words. Although we believe that our plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, we cannot assure you that our plans, intentions or expectations will be achieved.

Factors that could cause our actual results to differ materially from Highwoods’ current expectations include, among others, the following: buyers may not be available and pricing may not be adequate with respect to the planned dispositions of non-core assets; comparable sales data on which we based our expectations with respect to the sales price of the non-core assets may not reflect current market trends; the financial condition of our customers could deteriorate; our assumptions regarding potential losses related to customer financial difficulties could prove incorrect; counterparties under our debt instruments, particularly our revolving credit facility, may attempt to avoid their obligations thereunder, which, if successful, would reduce our available liquidity; we may not be able to lease or re-lease second generation space, defined as previously occupied space that becomes available for lease, quickly or on as favorable terms as old leases; we may not be able to lease newly constructed buildings as quickly or on as favorable terms as originally anticipated; we may not be able to complete development, acquisition, reinvestment, disposition or joint venture projects as quickly or on as favorable terms as anticipated; development activity in our existing markets could result in an excessive supply relative to customer demand; our markets may suffer declines in economic and/or office employment growth; increases in interest rates could increase our debt service costs; increases in operating expenses could negatively impact our operating results; natural disasters and climate change could have an adverse impact on our cash flow and operating results; we may not be able to meet our liquidity requirements or obtain capital on favorable terms to fund our working capital needs and growth initiatives or repay or refinance outstanding debt upon maturity; and the Company could lose key executive officers.

This list of risks and uncertainties, however, is not intended to be exhaustive. You should also review the other cautionary statements we make in “Risk Factors” set forth in our 2024 Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on forward-looking statements. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements to reflect any future events or circumstances or to reflect the occurrence of unanticipated events.

Contact:Brendan Maiorana Executive Vice President and Chief Financial Officer [email protected] 919-872-4924
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 stocknewsapi
ANNX
January 12, 2026 07:00 ET  | Source: Annexon Biosciences

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026

Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection

Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026

Strong Financial Position Funds Operations into Late 2027 Well Past Anticipated Key Milestones

BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today highlighted its 2026 strategic priorities and key milestones for its lead programs.

“2026 is a pivotal year for Annexon as we progress toward our first potential approval in GBS and pivotal Phase 3 data in GA,” said Douglas Love, president and chief executive officer of Annexon. “Building on more than a decade of expertise stopping acute and chronic neuroinflammation at its source, our two registrational programs have both demonstrated meaningful patient benefit in well-controlled trials by significantly protecting function in devastating diseases. As a result, vonaprument and tanruprubart both have the potential to reset the standard of care in their respective diseases and help millions of patients live their best lives.”

Mr. Love continued, “With tanruprubart’s Marketing Authorization Application (MAA) filed in Europe and the U.S./European FORWARD trial underway to support a planned U.S. BLA submission in 2026, we are increasingly focused on our vonaprument GA program and its upcoming pivotal data later this year. The strong biologic rationale and unprecedented effect on vision protection demonstrated in the Phase 2 trial provide confidence in the potential of vonaprument to replicate the findings and thereby preserve vision for the eight million people worldwide living with GA. With seasoned leadership and a strong financial position, we are energized by the year ahead and the potential to deliver significant value for patients and stakeholders.”

2026 Strategic Priorities and Key Milestones

Vonaprument– Potential to be the first targeted vision-preserving therapy for GA

Ongoing Phase 3 ARCHER II trial is a global, pivotal, sham-controlled, double-masked trial. The primary endpoint is the proportion of patients who experience a best corrected visual acuity (BCVA) 15-letter loss confirmed at two consecutive visits, measured at month 15. Enrollment of 659 patients completed ahead of schedule and exceeded target patient numbers. Patient selection profile similar to the Phase 2 trial, with enrichment strategies designed to include patients at higher risk for vision loss.  Global registration path established with U.S. and European regulators for ARCHER II, supporting the potential of vonaprument to be the first treatment approved for protection of vision in patients who have dry AMD with GA.Consistent with its neuroprotective mechanism, vonaprument provided significant protection of photoreceptors within the center of the retina necessary for visual acuity and significantly protected vision on multiple clinical measures.Annexon plans to host a GA Investor Day in March 2026 featuring management, key opinion leaders and retina experts to provide deeper insight on the vonaprument program and its potential impact in the GA landscape.Next Milestone: Topline Phase 3 ARCHER II trial data expected in second half of 2026.
Tanruprubart – Potential to be the first targeted fast-acting therapy for GBS

MAA filed with European Medicines Agency with comprehensive data package demonstrating rapid impact on markers of neuroinflammation and disease activity, and patients recovering faster and more completely on both disability and functional outcome measures in placebo-controlled studies. Also submitted data showing improved outcomes versus standard of care intravenous immunoglobulin (IVIg) or plasma exchange (PE) in a Real-World Evidence study.Ongoing open-label FORWARD study in the U.S. and Europe, designed to support a broad label across pediatric and adult patients and further expand the use of tanruprubart across geographies.Next Milestone: BLA submission with U.S./European data from FORWARD trial planned in 2026.
ANX1502 for Autoimmune Conditions – First-in-kind oral small molecule with convenient and flexible dosing

Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) in relation to food intake, and reduction in complement activity (as a measure of target engagement), and bilirubin (as a measure of hemolysis) is ongoing in proof-of-concept (POC) trial in patients with cold agglutinin disease (CAD).Objective measurements of clinical activity in CAD patients are anticipated to be translatable across a host of neuromuscular autoimmune diseases.Next Milestone: Update on POC trial in CAD anticipated in 2026.
About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to the potential therapeutic benefit of tanruprubart, if approved, compared to existing therapies; anticipated timing and results of regulatory interactions related to tanruprubart, including the timing of the company’s planned BLA submission to the U.S. Food and Drug Administration (FDA); the design, objectives and timing of the open-label tanruprubart FORWARD study; the company’s ability to achieve regulatory approval for tanruprubart; the potential therapeutic benefit of vonaprument; timing of and results from the Phase 3 ARCHER II trial; vonaprument’s distinct potential neuroprotective mechanism of action and potential to provide protection from vision loss; the potential for vonaprument to be the first drug approved for dry AMD with GA; the potential for vonaprument and tanruprubart to reset the standard of care; timing of proof-of-concept trial for ANX1502 in CAD and the company’s ability to provide an update upon completion of its POC trial in 2026; the company’s ability to commercialize its product candidates, if approved; the potential for the company to deliver significant value for patients and its stakeholders; and continuing advancement of the company’s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the potential for delays in the company’s clinical trials; the potential for the company’s product candidates to not receive regulatory approval, including if the FDA and comparable foreign regulatory authorities determine that the company’s submission package is not sufficient or require the company to provide additional data in patients that are not feasible to obtain; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the Securities and Exchange Commission. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Joyce Allaire
LifeSci Advisors
[email protected]

Media Contact:

Beth Keshishian
917-912-7195
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy stocknewsapi
LXEO
LX2020 generally well tolerated across ten participants with no clinically significant complement activation 

LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts

Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions

Company to host webcast today at 8:00 AM ET / 5:00 AM PT

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Across dose cohorts, LX2020 was generally well tolerated and led to robust transduction, increased PKP2 protein expression, and clinically meaningful improvement or stabilization in measures of arrhythmia burden in the majority of participants.

“These interim data from ten participants reinforce the favorable safety profile of LX2020 and demonstrate promising trends in transduction, protein expression, and reduction in arrhythmia burden at the high dose,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “We are encouraged by these preliminary results and look forward to advancing development of LX2020 given its therapeutic potential and ability to address the underlying cause of cardiac dysfunction and disease progression in PKP2-ACM.”

LX2020 Interim Update
Ten participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2x1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6x1013 vg/kg). Safety data are summarized for all ten participants dosed; efficacy data are inclusive of those participants with at least 6 months of follow-up as of the January 7, 2026 data cutoff date. Cardiac biopsy data are available for seven participants, as one participant in Cohort 1 declined post-dose biopsy.

Interim Safety Update (n=10)

LX2020 generally well tolerated across ten participants dosedNo clinically significant complement activationElevations in liver function tests (LFT) observed in five participants at the high dose, treated successfully with re-introduction of low-dose prednisone in three participants and increased prednisone and sirolimus in two participants per the trial protocol. All elevations resolved without complication, hospitalization or other treatmentNo participants discontinued from the HEROIC-PKP2 Phase I/II studyOne previously disclosed Grade 3 serious adverse event of sustained ventricular tachycardia (VT) was observed three months after dosing in a single participant at the high dose and assessed as possibly treatment related. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required
PKP2 Transduction and Expression (n=7 with post-treatment cardiac biopsies at 3 months)

Mean increase in PKP2 protein expression of 93% in the low-dose cohort (n=2) and 162% in the high-dose cohorts (n=5), assessed by western blotMean exogenous mRNA of 7.9E+04 copies per microgram of nucleic acid in the low-dose cohort (n=2) and 2.7E+05 copies per microgram in the high-dose cohorts (n=5)Mean vector copy number (VCN) of 1.5 in the low-dose cohort (n=1) and 3.3 in the high-dose cohorts (n=5); insufficient cardiac biopsy tissue available for participant 1 in low-dose cohort for VCN analysisAppropriate PKP2 colocalization observed at cardiac intercalated discs via immunofluorescence staining Clinical Data (n=8 with > 6 months of follow up)

Non-sustained ventricular tachycardia (NSVT) reduced or stabilized in the majority of participants; 22% mean improvement in high-dose cohorts at latest visit (n=5)Premature ventricular contractions (PVCs) reduced or stabilized in the majority of participants; 14% mean improvement in high-dose cohorts at latest visit (n=5)4 of 5 participants in high-dose cohorts report improvement relative to baseline on the Patient Global Impression of Change (PGIC) scale, a patient-reported outcome measureParticipants stable across other clinical measures including QRS duration, T-wave inversion, right ventricular ejection fraction (RVEF) and New York Heart Association (NYHA) Class Next Steps

HEROIC-PKP2 enrollment completed in Q4 2025; biopsy results pending for participants 9 and 1012-month data available for all high-dose participants in Q4 2026Regulatory engagement expected in 2026
Corporate Webcast Details
Lexeo Therapeutics will host a webcast at 8:00 AM ET / 5:00 AM PT today, January 12, 2026. Analysts and investors can participate by accessing the webcast live on the News & Events page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call.

About LX2020
LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion. LX2020 is being evaluated in the single-arm, open-label, multi-center HEROIC-PKP2 Phase I/II clinical trial (NCT06109181). LX2020 has been granted Orphan Drug and Fast Track designations by the FDA.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the anticipated benefits of its current product candidates. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 5, 2025, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Response:
[email protected]

Investor Response:
Ashley Kaplowitz
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference stocknewsapi
APLS
WALTHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2025, as well as its strategic priorities for continued growth across the business.
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026 stocknewsapi
FIVE
January 12, 2026 07:00 ET  | Source: Five Below, Inc.

Net Sales Increase of 23.2% to $1.5 Billion; Comparable Sales Increase of 14.5%

Increases Fourth Quarter and Full Year Fiscal 2025 Outlook

PHILADELPHIA, PA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE) ("Five Below" or the "Company") today announced net sales results for the quarter-to-date period from November 2, 2025 through January 3, 2026 ("Holiday Period"). Net sales for the Holiday Period increased by 23.2% to $1.47 billion from $1.19 billion in the comparable nine-week period from November 3, 2024 through January 4, 2025. Comparable sales for the Holiday Period increased by 14.5%.

Winnie Park, CEO of Five Below, stated, "We are incredibly pleased with our holiday performance, which demonstrates the effectiveness of the strategies we have been executing this year. With our maniacal focus on the customer: the kid and the kid in all of us, we offered amazing, trend-right products at exceptional value and began to create a better-connected customer journey. In combination with tight-knit collaboration and alignment throughout the company, we drove strong, broad-based results. Based on our holiday performance and forecast for January, we are raising our outlook for the fourth quarter and full year."

Ms. Park continued, "I am so proud of the teams and what they have accomplished this year. As we look toward 2026, I am excited by the tremendous opportunities ahead to build upon this momentum. We have clear strategic priorities and confidence in our ability to execute them successfully.”

Updated Outlook
This outlook includes the expected impact of tariffs currently in place and does not include the impact of share repurchases, if any.

Fourth Quarter Fiscal 2025 Outlook

Net sales of approximately $1.71 billionComparable sales increase of approximately 14.5%Diluted income per common share of $3.93 to $3.98 on approximately 55.6 million diluted weighted average shares outstanding; Adjusted diluted income per common share(1) of $3.95 to $4.00 (1) Adjusted diluted income per common share excludes the impact of nonrecurring or non-cash items which includes retention awards, net of income tax impacts.    Full Year Fiscal 2025 Outlook

Net sales of approximately $4.75 billionComparable sales increase of approximately 12.5%Diluted income per common share of $6.10 to $6.15 on approximately 55.5 million diluted weighted average shares outstanding; Adjusted diluted income per common share(2) of $6.30 to $6.35 (2) Adjusted diluted income per common share excludes the impact of nonrecurring or non-cash items which includes retention awards, costs associated with cost-optimization initiatives, execution of the inventory write-off, and costs incurred with the strategic acquisition of certain leases, net of income tax impacts.    As previously announced, management, including CEO Winnie Park and CFO Dan Sullivan, will participate in a fireside chat today at 10:00 a.m. Eastern Time at the 2026 ICR Conference. The event will be webcast live at http://investor.fivebelow.com/. An archived replay will be available two hours after the conclusion of the live event.

Non-GAAP Information:
This press release includes the Company’s current outlook for adjusted diluted income per common share, a non-GAAP financial measure. The Company believes that this non-GAAP financial measure provides its management with comparable financial data for internal financial analysis and provides meaningful supplemental information to investors. Non-GAAP financial measures have limitations as analytical tools. Other companies in the Company's industry may calculate this item differently than the Company does. This measure is not a measure of performance under GAAP and should not be considered as a substitute for the most directly comparable financial measure prepared in accordance with GAAP.

Forward-Looking Statements:
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be protected by the “safe harbor” provisions therein. Such statements reflect management’s current views and estimates regarding the Company’s industry, business strategy, goals, expectations and outlook concerning its market position, operations, margins, profitability, capital expenditures, liquidity and capital resources, store count potential and other financial and operating information. Investors can identify these statements by the fact that they use words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future” and similar terms and phrases. The Company cannot assure investors that future developments affecting the Company will be those that it has anticipated. Although we believe there is a reasonable basis for such forward-looking statements, our actual results may differ materially from these expectations due to risks that include, but are not limited to, risks related to disruption to the global supply chain, increased cost of freight, constraints on shipping capacity to transport inventory or the timely receipt of inventory, risks related to the Company’s strategy and expansion plans, risks related to our ability to attract, retain, and motivate qualified executive talent, risks related to disruptions in our information technology systems and our ability to maintain and upgrade those systems, risks related to our ability to successfully implement our online retail operations, risks related to cyberattacks or other cyber incidents, such as the failure to secure customers’ confidential or credit card information, or other private data relating to our crew or the Company, including the costs associated with protection against or remediation of such incidents, risks related to increased usage of machine learning and other types of artificial intelligence in our business, and challenges with properly managing its use, risks related to our ability to select, obtain, distribute and market merchandise profitably, risks related to our reliance on merchandise manufactured outside of the United States, including risks related to direct and indirect impact of current and potential tariffs imposed, threatened, or proposed by the United States on foreign imports, including, without limitation, the tariffs themselves, any counter-measures thereto (in addition to any applicable foreign trade restrictions, generally) and any indirect effects on consumer discretionary spending, risks related to the availability of suitable new store locations and the dependence on the volume of traffic to our stores and website, risks related to our dependence on our executive officers, senior management and other key personnel or our ability to hire additional qualified personnel, risks related to changes in consumer preferences and economic conditions, risks related to increased operating costs, risks related to inflation and increasing commodity prices and related effects, such as a reduction in our unit sales (including an inability to increase sales), damage to our reputation with our customers, our becoming less competitive in the marketplace or exposure to fraud or theft due to customer payment-related risks, risks related to potential recessions and systematic failure of the banking system in the United States or globally, risks related to natural disasters, adverse weather conditions, pandemic outbreaks, global political events, war, terrorism or civil unrest (including any negative effects to our business and result of operations), risks related to building, operating or expanding shipcenters or network capacity, risks related to our ability to successfully manage inventory balance and inventory shrinkage, quality or safety concerns about the Company’s merchandise (including the impact of product and food safety claims and legislation), increased competition from other retailers including online retailers, risks related to the seasonality of our business, risks related to our ability to protect our brand name and other intellectual property, risks related to customers’ payment methods, risks associated with the restrictions imposed by our indebtedness on our current and future operations, the impact of changes in tax legislation and accounting standards, risks related to our insurance programs and their effect on our financial performance and risks associated with leasing substantial amounts of space and owning real property. For further details and a discussion of these risks and uncertainties, see the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. If one or more of these risks or uncertainties materialize, or if any of the Company’s assumptions prove incorrect, the Company’s actual results may vary in material respects from those projected in these forward-looking statements, despite the Company’s reasonable basis for such statements. Any forward-looking statement made by the Company in this news release speaks only as of the date on which the Company makes it. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

About Five Below:
Five Below is a leading growth retailer offering trend-right, extreme value, high-quality products loved by the kid and the kid in all of us. We believe life is better when customers are free to "let go & have fun" in an amazing experience filled with unlimited possibilities. With most items priced between $1 and $5 and some extreme value items priced beyond $5, Five Below makes it easy to say YES! to the newest, coolest stuff across awesome Five Below worlds: Candy, Style, Party, Room, Create, Tech, Sports and New & Now. Founded in 2002 and headquartered in Philadelphia, Pennsylvania, Five Below today has over 1,900 stores in 46 states. For more information, please visit www.fivebelow.com or follow @fivebelow on TikTok, Instagram and Facebook.

Investor Contact:
Five Below, Inc.
Christiane Pelz
Vice President, Investor Relations
[email protected]
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range stocknewsapi
BCRX
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)–

–ORLADEYO net revenue expected to be between $625 million and $645 million in 2026–

–BioCryst expects continued non-GAAP profitability in 2026 even after expected close of the proposed acquisition of Astria Therapeutics in Q1 2026–

RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO (berotralstat) net revenue for the fourth quarter and full year 2025. The company also provided guidance for ORLADEYO net revenue, total revenue, and operating expenses for full year 2026.

“2025 was a transformative year for BioCryst. Continued strong demand for ORLADEYO and outstanding patient outcomes have solidified its position as the leading oral, once-daily prophylaxis treatment for HAE. The successful sale of our European ORLADEYO business further strengthened our financial position, and the proposed acquisition of Astria marks an exciting step toward expanding our impact for HAE patients. With our advancing pipeline, flexibility to continue pursuing value-creating business development opportunities, and dedication of our exceptional team, we are confident in our ability to deliver innovative treatments for rare disease patients and drive sustainable growth well into the future,” said Charlie Gayer, President and Chief Executive Officer.

Preliminary Fourth Quarter and Full Year 2025 ORLADEYO Revenue, 2026 ORLADEYO and Total Revenue Outlook, and Cash Position at Year-End 2025
Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2025 was $151 million (+22 percent y-o-y; +36% y-o-y on a comparable basis, excluding European ORLADEYO revenue for the fourth quarter of 2024).

Preliminary, unaudited ORLADEYO net revenue for full year 2025 was $601 million (+37 percent y-o-y), beating the company’s prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue for the full year 2025, preliminary, unaudited ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis).

The company expects full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million, and expects full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million.

Preliminary, unaudited cash, cash equivalents, restricted cash & investments as of December 31, 2025, were $338 million.

Operating Expense Outlook
The company expects full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $380 million and $390 million. This does not include operating expenses from Astria Therapeutics after the expected close of the acquisition in Q1 2026.

Upon the expected close of the Astria acquisition, the company expects additional non-GAAP operating expenses in 2026 to be between $70 million and $80 million to support the ongoing Phase 3 enrollment of navenibart and commercial readiness manufacturing activities. These costs are expected to trend down over the next two years as the trial is completed and the full impact of operational synergies is realized.

Full Year 2026 Financial GuidanceItemAs of January 12, 2026ORLADEYO revenue$625 million to $645 millionTotal revenue$635 million to $660 millionNon-GAAP operating expense$380 million to $390 millionNon-GAAP operating expense including Astria acquisition$450 million to $470 million   Presentation at 44th Annual J.P. Morgan Healthcare Conference
The company will present today at 1:30 p.m. ET at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. A link to the live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Non-GAAP Financial Measures
The information furnished in this release includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP.”

We believe providing these non-GAAP measures, which show our results with these items adjusted, is valuable and useful since they allow management and investors to better understand the company’s financial performance in the absence of certain non-cash items such as stock-based compensation and certain special events and allow investors to more accurately understand our current and past period results and more easily compare them to future results. These non-GAAP measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue or operating income.

Our references to the “non-GAAP” financial measure of preliminary, unaudited 2025 ORLADEYO revenue, excluding European ORLADEYO revenue for the full year 2025, constitutes a non-GAAP financial measure. It refers to our preliminary GAAP results, adjusted to show the results without including $38 million of European ORLADEYO revenue for the nine months ended September 30, 2025. Our measure of 36% y-o-y growth on a comparable basis for preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2025 was calculated using the non-GAAP financial measure of Q4 2024 ORLADEYO net revenue, adjusted to exclude $13 million of European ORLADEYO revenue for the three months ended December 31, 2024. Our measure of 43% y-o-y growth on a comparable basis for preliminary, unaudited ORLADEYO net revenue for the full year 2025 was calculated using the non-GAAP financial measure of full year 2024 ORLADEYO net revenue, adjusted to exclude $43 million of European ORLADEYO revenue for the twelve months ended December 31, 2024. Our reference to expected non-GAAP profitability excludes stock-based compensation, restructuring and transaction-related costs.

We also provide our non-GAAP operating expense outlook for full year 2026, which refers to our expected GAAP operating expense, excluding stock-based compensation, restructuring and transaction-related costs. We have not provided a reconciliation against the comparable forward-looking GAAP measure because we are unable to predict with reasonable certainty the full amount of stock-based compensation expense or restructuring and transaction-related costs for the full year 2026 without unreasonable effort. Stock-based compensation expense is uncertain and depends on various factors, including our future hiring and retention needs, as well as the future fair market value of our common stock, which is difficult to predict and subject to change. In addition, we are unable to predict with reasonable certainty the full amount of restructuring and transaction-related costs as the closing of the proposed Astria acquisition is still pending and the related costs are dependent on various factors that have not yet occurred. The actual amount of stock-based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding preliminary, unaudited results and future results, performance or achievements, expectations regarding BioCryst’s growth and expenses, and statements related to BioCryst’s acquisition of Astria Therapeutics, Inc. (the “Merger”), including the expected benefits of the Merger, anticipated timing of the closing of the Merger, the anticipated financial impact of the Merger, BioCryst’s or the combined company’s performance following the Merger, including future financial and operating results, and anticipated approval and commercialization of navenibart. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any preliminary, unaudited results and future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions, including assumptions related to the expected date of closing of the Merger and the potential benefits thereof, and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its pipeline development plans, including meeting the expected timelines; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; timing for achieving or sustainability of profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results or may not be achieved on the expected timelines, or at all, based on market factors and BioCryst’s ability to execute its operational and budget plans; actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges; the occurrence of any event, change or other circumstances that could give rise to the right of BioCryst or Astria to terminate the definitive agreement governing the Merger; the failure to obtain Astria stockholder approval or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits of the Merger, including anticipated synergies, are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where BioCryst and Astria do business; the significant indebtedness BioCryst expects to incur in connection with the Merger and the need to generate sufficient cash flows to service and repay such debt; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the Merger; and risks relating to the potential dilutive effect of shares of BioCryst common stock to be issued in the Merger. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission (the “SEC”), specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
Investors:
[email protected] 

Media:
[email protected] 
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference stocknewsapi
MDWD
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
JPMorgan's looming question: What happens when CEO Jamie Dimon leaves? stocknewsapi
JPM
watch now

As Wall Street's top bankers huddled in New York last month, preparing to convince Elon Musk's SpaceX that they should be chosen to lead its upcoming IPO, one firm wasn't letting its star advisor miss the bake-off.

Among the squad of JPMorgan Chase investment bankers flying 2,500 miles west to California to pitch SpaceX was the lender's boss, billionaire CEO Jamie Dimon, people with knowledge of the trip told CNBC.

The morning after that pitch meeting, on Dec. 19, Dimon was already back in his customary early Friday perch: sitting in his bank's New York lobby, taking meetings in full view of the thousands of employees streaming through the building's turnstiles.

The whirlwind few days highlight the reality of Dimon's singular impact on JPMorgan, the world's largest bank by market capitalization.

Dimon marks his 20th anniversary as CEO this month and remains deeply involved across the sprawling businesses of JPMorgan, a giant across Wall Street and Main Street with $4.6 trillion in assets. Half a dozen executives across investment banking, asset management and consumer banking echoed that view.

Which makes the inevitable questions surrounding Dimon's tenure loom large as he approaches 70 years of age. Dimon has for years maintained, somewhat tongue-in-cheek, that his retirement was perpetually 5 years away. In 2024, for the first time, he acknowledged that window was shrinking.

Will JPMorgan's era of dominance be over when Dimon exits as CEO?

"Given his track record, anybody else would be a downgrade," said Ben Mackovak, a bank board member and investor through his firm Strategic Value Bank Partners.

"I'm sure somebody else could grow into the role and surprise people," Mackovak said. "But on day one, no one is going to be as qualified to run that bank as Jamie."

In two decades, Dimon took a middle-of-the-pack American lender and, with his unique combination of judgment, paranoia, attention to detail and scope of vision, created a juggernaut of finance that the world hadn't seen before.

During calm times, he invested aggressively for the future, and during periods of tumult, like 2008 and 2023, he avoided pitfalls that consumed other banks, allowing him to snap up three failed institutions.

Over the past 20 years, the bank's annual net income soared more than 500% to $58.5 billion in 2024. The firm reports full-year 2025 results on Tuesday.

Now, at a market cap of roughly $900 billion, JPMorgan is worth nearly as much as the next three largest U.S. banks combined: Bank of America, Citigroup and Wells Fargo.

Besides running JPMorgan, Dimon has taken on an outsized role in global finance as a top voice explaining market gyrations or emerging risks and influencing regulators amid policy shifts. It was Dimon's recession warning on a Fox News segment in April that helped convince President Donald Trump to pivot on his trade policy, igniting a historic relief rally.

"It's just the aura he has, the credibility that he's built up in the markets," said Fitch Ratings analyst Chris Wolfe. "The minute you step out of that role, it's not like you can just hand that over, your successor doesn't automatically inherit that. I think that's the real challenge."

Potential successorsThe question of who could take over for Dimon — who was already a cancer survivor when he nearly died in 2020 from a ruptured aorta — has been openly discussed among investors for more than a decade.

To investors, his most likely successor is currently Marianne Lake, head of the firm's giant consumer bank and former CFO of the company, followed by Doug Petno and Troy Rohrbaugh, the co-heads of the firm's commercial and investment bank.

Other contenders include asset and wealth management head Mary Erdoes and CFO Jeremy Barnum.

"If investors were to do a straw poll today, they'd probably pick Marianne," said Truist bank analyst Brian Foran.

"The running joke is that she's a human supercomputer when it comes to banking," Foran said. "Really, the only question mark people have about her is, she's so analytical, can she do the kind of 'rah-rah' stuff to inspire the sales force?"

Wells Fargo banking analyst Mike Mayo hypothesized that JPMorgan stock could immediately drop 5% if Dimon were to suddenly exit, regardless of the named replacement. (The bank has said Dimon would serve as chairman even after relinquishing the CEO role.)

It's a somewhat common occurrence on Wall Street for companies with iconic CEOs: The stock premium shrinks, at least for a period, when their longtime leaders announce their departures. For instance, Berkshire Hathaway shares trailed the S&P 500 last year after Warren Buffett said he was stepping down as CEO.

'Never going to quit' When asked about CEO succession, JPMorgan executives say that Dimon is as plugged in as ever, and unlikely to step down soon.

Depending on how long he sticks around, that means it's not necessarily his current direct reports like Lake, Petno and Rohrbaugh who are in line, but more junior executives now being groomed and evaluated for leadership roles, they told CNBC.

"There's a lot of work going into imagining that day without him," said a JPMorgan executive who asked not to be named speaking about his boss. "If he stays until he's 85, it's not his direct reports that are going to be next in line, its maybe one or two levels down from today."

"Does he leave a huge vacuum? Yes," said the executive. "It's not fatal, though, because we've been planning for it. I think there's combinations of people that together can create the same outcome."

The CEO of a commercial bank and former JPMorgan executive, who described Dimon as a mentor, also said he didn't think Dimon would step down soon.

"Jamie's never going to quit," said the CEO, who asked for anonymity to speak candidly. "What else would he do where he's as important as he is now? His friends are all people from work. He loves it."

Still, beyond the day-to-day management of a company with 318,000 employees, Dimon seems intent on setting up JPMorgan for a future without him.

Legacy values In recent months, Dimon oversaw the completion of the bank's new $3 billion headquarters in midtown Manhattan and announced a $1.5 trillion initiative to bolster industries crucial to U.S. interests.

And, perhaps most crucially, he continues to instill his values into the firm's management team.

Last year, at a conference for JPMorgan's top 400 executives, Dimon rattled off a list of once-great companies that died though mismanagement. Finance is especially prone to this threat, because of the temptation to manipulate numbers for short-term gain, he said.

"Travelers blew up. Citi blew up, twice. Bear Stearns failed, Lehman failed, I'm here because Bank One screwed up a bunch of businesses," Dimon said, referring to a predecessor firm to JPMorgan.

"If you look at these things, it's complacency, it's bureaucracy, it's arrogance. A lot of it is dishonest numbers. Failure to set standards," Dimon said. "These are the cancers that kill companies."

Nobody knows when Dimon's last day as CEO will come, except to know that it is approaching. After adjusting his standard 5-year retirement answer to hint at a sooner departure, Dimon hasn't advanced that clock any further.

"As great as he is, he can't do this forever," said Barclays banking analyst Jason Goldberg. "Every day that passes, you're a day closer to the end."

— CNBC's Gabriel Cortes contributed to this report.
2026-01-12 12:09 2mo ago
2026-01-12 07:00 2mo ago
Palantir Technologies (NASDAQ: PLTR) Price Prediction and Forecast 2026-2030 for January 12 stocknewsapi
PLTR
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Shares of Palantir Technologies Inc. (NASDAQ:PLTR) sold off at the start of the new year, losing 14.05% over the first five trading sessions. But over the past five trading sessions, the stock is up 1.68%. The damage from a rotation out of AI stocks that began in late 2025 continues, but PLTR remains up 173.15% over the past year. Since going public on Oct. 2, 2020, it has gained an eye-popping 1,829.24%.

When Palantir reported Q3 earnings on Nov. 3, 2025, it topped quarterly estimates and issued strong guidance, assigning its strong growth to adoption of its AI software platforms. The company beat on the top and bottom lines, with EPS of 21 cents versus 17 cents expected, and revenue of $1.18 billion versus $1.09 billion expected.

In September 2025, the company announced a new defense partnership with the U.K. government valued at £1.5 billion. In late July, it was announced that Palantir secured a $10 billion software and data contract with the U.S. Army. In May, the Trump administration rewarded a federal contract worth hundreds of millions to Palantir with the objective of creating a database on every U.S. citizen. On April 21, Investor’s Business Daily reported that Palantir won an immigration tracking federal contract from the U.S. Immigration and Customs Enforcement (ICE). The ICE contract, which is said to be worth $30 million, will be used to create an immigration Lifecycle Operating System to be used in deportations.

Big Data is expected to be big business in the years ahead. According to platform provider Edge Delta, the market for data services is projected to grow from $220.2 billion in 2023 to $401.2 billion by 2028 — an increase of 82.2%. Palantir is a major player in the space. The company was co-founded by entrepreneur and venture capitalist Peter Thiel, who was also the co-founder of PayPal Holdings (NASDAQ:PYPL) and the first outside investor in Facebook.

The company stands as one of Big Data’s industry dominators. However, finding data-driven assessments of where the company’s stock will be in the medium and long term can be complicated. With Wall Street analysts only going as far as providing one-year price targets, it can be difficult for investors to accurately gauge predictions for stocks like these over longer horizons. But for buy-and-hold investors who want to know where Palantir’s stock might be several years down the road, 24/7 Wall St. has done the legwork and can provide insights around the numbers coming from the company, and which market segments the company is operating in that are most exciting to us.

Palantir’s Results Since 2020 The following is a table that summarizes the performance in share price, revenues, and profits (net income) of PLTR from its inception in 2020 through the end of 2024:

Year Share Price Revenue* Net Income* 2020 $23.55 1.092 1.166 2021 $18.21 1.541 .520 2022 $6.29 1.905 .373 2023 $17.17 2.225 .209 2024 $75.63 2.87 .462 2025 $177.75 TBD TBD *Revenue and net income in $billions

Since going public, Palantir saw its revenue grow experience explosive growth while net income has fallen, although it has ticked up from 2023 to 2024. That drop in net income can be easily attributed, though. The company’s IPO in 2020 raised $2.6 billion, but that was shortly followed by 2022’s year-long bear market. Nonetheless, by 2023, the Big Data firm was able to reach profitability for the first time in its then 20-year history.

The momentum has continued with a series of earnings beats, most recently in March when Palantir reported that in Q1, the company beat on EPS by 1.11% and revenue by 2.52%. That marked the seventh consecutive EPS beat for the company, and the ninth in 10 quarters.

Key Drivers of Palantir’s Stock Performance 1. Palantir’s Expansion and Adoption of AI and Machine Learning Platforms: In addition to its AI bootcamps, the company offers clients four platforms to help manage, analyze, and secure their sensitive data. The first, AIP, focuses on introducing AI into companies’ operations. Foundry, Palantir’s operating system for modern enterprises, allows customers to harmonize and automate decision-making in complex settings while bridging the divide between core business and operating teams with data teams and modeling teams. Gotham, its third platform, focuses on a global scale, with the company billing the software as the weapons system for decision-making, which has extensive applications in defense and combat. Finally, Palantir’s Gotham platform is an operating system for continuous delivery with a focus on deployment — that is, integrating a machine-learning model into a production environment. Palantir is also making a strong push into modular sales to attract smaller clients and scale them with customer solutions as they grow. This strategy will significantly expand Palantir’s customer base and provide years of earnings growth.

2. Government Demand: Palantir’s revenue from government sources has outperformed revenue from commercial sources each year since 2020, with notable growth every year. In 2023, government-sourced revenue regifted $1.222 billion compared to $1.002 billion for commercially-sourced revenue. The company’s government clients include the United States Intelligence Community and the United States Department of Defense (DoD). Palantir’s software as a service (SaaS) is one of only five that are authorized for the DoD’s Mission Critical National Security Systems. By revenue, the U.S. government is the company’s largest client, and with ever-growing defense spending as a fixture of the U.S. federal government’s budget, the relationship is ripe. Bottom line, government demand is still core to Palantir, and with modular sales, the company will pack a double punch of private and public.

3. Space Partnerships: Last June, Palantir signed a strategic partnership with Voyager Space with the aim of leveraging its AI intelligence to drive innovation in space technology. According to its press release, Voyager will now fully integrate Palantir’s AI capabilities into its defense solutions, enhancing communications, military research and development, and bolstering intelligence and space research with the end goal of making space more accessible to the defense community. Voyager will be using Palantir’s Foundry platform. This marks the second strategic space partnership for the company, which also signed an agreement with Starlab Space on June 20, 2024. In this deal, Palantir became the exclusive supplier of enterprise-wide software data management solutions for the Starlab commercial space station — a planned low Earth orbit venture that is expected to launch no later than 2028 and is a joint venture between Starlab and Airbus.

Palantir (PLTR) Stock Prediction in 2026 According to Wall Street analysts, the current median one-year price target for Palantir’s stock is $177.49, which represents potential upside of 7.08% from today’s share price. Of the 17 analysts covering PLTR, the stock is a consensus “Hold,” with 11 analysts assigning it a “Hold” rating, four assigning it a “Buy” rating and two assigning it a “Sell” rating.

24/7 Wall St.’s year-end 2026 forecast for Palantir’s stock price is $202.50 with EPS coming in right at 56 cents, based on strong CAGR growth in sales of government contracts, upwards of 26% annually, and having factored for $3.186 billion in forecast revenue. Our price target represents 14.09% upside potential from the current stock price.

Palantir (PLTR) Stock Forecast Through 2030 Year Revenue* Net Income* EPS 2025 $3.467 $1.178 $0.47 2026 $4.198 $1.465 $0.56 2027 $5.203 $1.686 $0.71 2028 $6.185 $2.050 $0.87 2029 $7.300 $2.496 $1.06 2030 $8.482 $2.990 $1.27 *Revenue and net income in $billions

Palantir (PLTR) Stock Price Target for 2026–2030 On the back of forecast revenue in excess of $8 billion, we expect Palantir’s net income to surpass $2 billion for the first time, and post an EPS of $1.27. We expect free cash flow to approach $6 billion by posting $5.895 billion. The price projection for 2030 is $288.00, or 62.26% potential upside from today’s stock price.

Year Price Target %Change From Current Price 2026 $202.50 14.09% 2027 $235.50 37.75% 2028 $244.50 37.75% 2029 $267.00 50.43% 2030 $288.00 62.26% The New Report Shaking Up Retirement Plans  You may think retirement is about picking the best stocks or ETFs, but you’d be wrong. Even great investments can be a liability in retirement. It’s a simple difference between accumulating vs distributing, and it makes all the difference.

The good news? After answering three quick questions many Americans are reworking their portfolios and finding they can retire earlier than expected. If you’re thinking about retiring or know someone who is, take 5 minutes to learn more here.
2026-01-12 12:09 2mo ago
2026-01-12 07:01 2mo ago
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy stocknewsapi
DTIL
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026

PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026

Unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, 2025, anticipated to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points.

“We continue to make steady, disciplined progress across our clinical-stage programs,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “With multiple dosing cohorts underway in our global Phase 1/2a ELIMINATE-B trial, our first-in-class gene editing approach for DMD entering the clinic in early 2026, and cash runway through 2028, we expect continued operational excellence this year with clear clinical and regulatory milestones for these potentially transformative therapies.”

PBGENE-HBV -Dose Finding Phase 1/2a ELIMINATE-B Trial in Chronic Hepatitis B

PBGENE-HBV is uniquely designed to potentially achieve a complete cure of hepatitis B by eliminating cccDNA, preventing the chance of viral relapse, and inactivating integrated HBV DNA. The data reported at AASLD in November 2025 as of the October 31st cutoff date showed clear positive evidence of dose-dependent effects and antiviral activity in all patients. The data also included paired biopsies providing the first molecular evidence of successful viral DNA gene editing in patients with hepatitis B.

The safety data showed PBGENE-HBV to have no dose-limiting toxicities at doses up to 0.8 mg/kg (Cohort 3) following the first administration. Adverse events across 22 total administered doses in 9 patients in the first 3 dose cohorts (0.2 mg/kg, 0.4 mg/kg, and 0.8 mg/kg) were predictable, manageable, and transient, including hypotension in the higher dose cohorts. Transaminase elevations were transient without elevations in bilirubin and resolved without intervention, and platelet fluctuations were transient and asymptomatic.

Given the safety profile after multiple repeat doses and durability of response with PBGENE-HBV, Precision has administered additional doses in Cohort 3 and in parallel commenced dosing two additional cohorts as previously planned to investigate a shorter dosing interval. Cohort 4 is being dosed at 0.4 mg/kg every 4 weeks and Cohort 5 at 0.65 mg/kg every 4 weeks to evaluate the potential for an optimized therapeutic index. To date, 12 participants have completed at least one dose administration of PBGENE-HBV across Cohorts 1 through 5.

Additional biopsy data is expected in the first half of 2026 building upon the first clinical evidence of viral gene editing for PBGENE-HBV which was shared at AASLD. In addition, Precision expects to complete dosing Cohorts 3, 4, and 5 and choose the optimal dosing regimen to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the trial.

“We continue to advance PBGENE-HBV through Part 1 of the ELIMINATE-B dose-finding study and are encouraged by the activity we are seeing at all dose levels,” said Cindy Atwell, Chief Development and Business Officer. “As part of our dose optimization efforts, we are evaluating different levers for PBGENE-HBV across escalating doses, frequency of doses, and number of administrations in order to maximize the therapeutic index of PBGENE-HBV and start the expansion phase. We look forward to sharing further details at hepatitis-focused medical conferences in 2026.”

PBGENE-DMD - Phase 1/2 FUNCTION-DMD Trial in Duchenne Muscular Dystrophy (DMD) Patients

PBGENE-DMD, a novel first-in-class gene editing therapy, utilizes a gene excision approach, which is clearly differentiated from existing microdystrophin and exon skipping treatments. PBGENE-DMD is designed to potentially provide durable functional muscle improvement for DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD. A single AAV encodes two ARCUS proteins designed to permanently edit a patient’s DNA within the dystrophin gene, resulting in a naturally-expressed, near full-length, functional dystrophin protein. Supported by robust preclinical evidence, PBGENE-DMD is designed to drive functional improvement over time by targeting muscle satellite cells.

Following clearance of the investigational new drug (IND) application, the FUNCTION-DMD Phase 1/2 clinical trial is expected to dose the first patient in late-Q1 or early-Q2 2026. The study will employ an appropriate immune modulation regimen and safety monitoring program to treat ambulatory patients with mutations in exons 45-55 at world class specialized DMD clinical sites. Initial data from multiple patients is expected by year end 2026, with early efficacy assessed by the percentage of near full-length dystrophin protein expression from muscle biopsies. Following supportive data from at least 10 DMD patients, the company would meet with the FDA to align on a regulatory path forward.

Partnered Programs

ECUR-506, being developed by iECURE, uses Precision BioSciences’ ARCUS nuclease and is being evaluated as a potentially curative treatment for neonatal onset OTC deficiency in the ongoing OTC-HOPE study. Recently, iECURE reached alignment with the U.S Food and Drug Administration (FDA) on the primary and key secondary efficacy endpoints, comparators and study size for the ongoing OTC-HOPE study which could support a Biologics License Application. In addition, ECUR-506 was granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for neonatal onset OTC deficiency. iECURE’s receipt of these regulatory milestones is supported by encouraging clinical data from the ongoing OTC-HOPE clinical study, including a complete clinical response observed in the first infant treated with ECUR-506. iECURE expects to release data from the ongoing clinical trial in the first half of 2026.

Azer-Cel, a novel allogeneic CAR T treatment originally created by Precision, is being developed by Imugene for diffuse large B-cell lymphoma. Imugene’s recent FDA discussions have reached clear alignment across key elements required to advance azer-cel into a pivotal study including dosing regimen, patient population, endpoints, and manufacturing readiness.

Precision received an $8 million milestone payment in the fourth quarter of 2025 as a result of Imugene’s progress with Azer-Cel.

Azer-Cel is also being developed by TG Therapeutics. Enrollment for patients with progressive multiple sclerosis is ongoing in a Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases. Precision is eligible for additional milestone payments from TG Therapeutics, including a $7.5M near term clinical milestone.

Financial Position

Although it has not finalized its full financial results for the year ended December 31, 2025, Precision expects to report it had approximately $137 million in cash, cash equivalents, and restricted cash. Existing cash and cash equivalents, potential near-term consideration to be received from licensees, continued fiscal and operating discipline, and availability of its ATM facility are expected to provide sufficient cash runway through 2028.

About the ELIMINATE-B Trial:

The Phase 1/2a ELIMINATE-B study is currently enrolling HBeAg-negative chronic hepatitis B patients at world-class sites in Hong Kong, New Zealand, United States and Moldova. The goal of the study is to define the optimal dose and number of dose administrations for safely eliminating cccDNA and inactivating integrated HBV DNA. With regulatory approval already granted, Precision expects to expand the study to clinical trial sites in the U.K. and continue accelerating recruitment and evaluation of a genetically diverse patient population in the Phase 1/2a study.

About FUNCTION-DMD Trial:

The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD. Pending IND clearance, the clinical trial is anticipated to begin dosing patients at world class sites starting in late Q1/early-Q2 with initial clinical data from multiple patients expected later in 2026.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA such as in the Company’s PBGENE-HBV program), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company’s DMD program).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations about operational initiatives, strategies, further development including dose expansion, and timing of additional updates or data releases of PBGENE-HBV, PBGENE-DMD, and the OTC-HOPE trial; translation of results in preclinical studies of ARCUS nucleases to clinical studies in humans; the design of PBGENE-HBV to potentially achieve a complete cure of hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA at the source of hepatitis B, preventing the chance of viral relapse; the potential tolerability and hepatic safety for repeat administrations of PBGENE-HBV to drive antiviral responses; the expectation of biopsy data in the first half of 2026 and to complete dosing Cohorts 3, 4, and 5 and choose the optimal dosing regimen to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the ELIMINATE-B trial; expected regulatory processes, including an investigational new drug (IND) clearance for PBGENE-DMD; expected dosing of the first patient in the Phase 1 clinical trial of PBGENE-DMD in late Q1 or early Q2 of 2026; expectations of initial data for multiple patients in the PBGENE-DMD program by year end 2026; expected communication with the FDA and alignment on regulatory path forward following supportive data from at least 10 DMD patients; the expected cash, cash equivalents, and restricted cash balance as of December 31, 2025; and the expected cash runway and the sufficiency of the cash runway to fund of data milestones for PBGENE-HBV and PBGENE-DMD through 2028. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “belief”, “believe,” “contemplate,” “could,” “design,” “designed,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “strive,” “suggest,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; our ability to advance product candidates into, and successfully design, implement and complete, clinical trials; changes in interim “top-line” and initial data that we announce or publish; our current and future relationships with and reliance on third parties including suppliers and manufacturers; and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025, and September 30, 2025 as any such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (SEC), which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

More News From Precision BioSciences, Inc.
2026-01-12 12:09 2mo ago
2026-01-12 07:02 2mo ago
FIS Launches Industry-First Offering Enabling Banks to Lead and Scale in Agentic Commerce stocknewsapi
FIS
JACKSONVILLE, Fla.--(BUSINESS WIRE)--FIS® (NYSE: FIS), a global leader in financial technology, today announced the launch of its first offering to enable agentic commerce on the heels of announcing the close of the acquisition of its FIS Total Issuing™ Solutions portfolio. FIS’ new agentic commerce offering is the first to enable banks to safely and securely conduct commerce with AI agents and card networks.

In agentic commerce transactions, AI functions as a personal digital assistant that can source, negotiate and complete purchases or financial transactions using preapproved payment methods on behalf of a customer. McKinsey forecasts that agentic commerce could generate as much as $1 trillion in orchestrated U.S. retail revenue by 2030, and as much as $3 trillion to $5 trillion globally1.

Through collaboration with global payment networks, AI-initiated transactions are executed within existing authorization, authentication and dispute frameworks trusted by banks, merchants and consumers worldwide.

Financial services companies are integral to agentic commerce because they provide the infrastructure, security protocols and payment systems that allow AI agents to transact safely and seamlessly. As agentic payment transactions accelerate, this new offering empowers FIS’ bank clients to remain central to this new method of commerce by providing technologies that help banks identify and authorize agent-initiated transactions and support related compliance efforts. Importantly, this will allow FIS’ banking clients to institute fraud protections on behalf of consumers.

Expected to be available by the end of Q1 2026 to all FIS issuing bank clients, this offering is designed to allow issuers to use relevant know your agent (KYA) data and card details securely. It is also designed to enable issuers to benefit from fewer chargebacks, merchants to benefit from higher transaction approval rates and fewer false declines, and consumers to benefit from enhanced fraud protection and seamless experiences across traditional and agentic AI purchasing.

“FIS has spent decades helping financial institutions navigate technological inflection points. Agentic commerce represents a next fundamental shift in how consumers interact with financial services, and our role is to ensure banks not only participate in this transformation but lead it,” said Stephanie Ferris, CEO and President, FIS. “By combining our global payments scale, our newly acquired issuing capabilities, and partnerships with industry leaders like Mastercard and Visa, we're enabling AI-powered solutions that keep our clients at the center of commerce while enhancing security, reducing friction and improving experiences for the consumers they serve.”

Visa and Mastercard are key strategic partners in this launch, with Visa Intelligent Commerce and Mastercard enabling AI agents to initiate and safely conduct transactions across their networks. The initial use cases focus on transaction authorization, fraud and customer servicing. FIS plans to work with these partners and pilot clients to deliver a set of initial use cases including transaction authorization, fraud, loyalty and customer servicing, and more broadly, collaborate on an expanded set of data-powered uses cases over time.

About FIS

FIS is a financial technology company providing solutions to financial institutions, businesses and developers. We unlock financial technology to the world across the money lifecycle underpinning the world’s financial system. Our people are dedicated to advancing the way the world pays, banks and invests, by helping our clients to confidently run, grow and protect their businesses. Our expertise comes from decades of experience helping financial institutions and businesses of all sizes adapt to meet the needs of their customers by harnessing where reliability meets innovation in financial technology. Headquartered in Jacksonville, Fla., FIS is a member of the Fortune 500® and the Standard & Poor’s 500® Index. To learn more, visit FISglobal.com. Follow FIS on LinkedIn, Facebook and X.
2026-01-12 12:09 2mo ago
2026-01-12 07:02 2mo ago
Pet Valu Appoints Carmen Fortino and Matt Reindel to Board of Directors stocknewsapi
PTVLF
MARKHAM, Ontario, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, is pleased to announce the appointment of Carmen Fortino to its board of directors (the “Board”) effective today, succeeding Kevin Hofmann, and the anticipated appointment of Matt Reindel to the Board effective April 1, 2026, to succeed Patrick Hillegass.

Mr. Fortino brings over five decades of Canadian retail experience, predominantly in the food retail sector. He is currently Executive Vice President, National Supply Chain and Procurement at Metro Inc. (TSX: MRU), overseeing strategic sourcing and distribution for one of Canada’s leading food retailers. Prior to joining Metro in 2014, Mr. Fortino held several leadership positions in the health and wellness space, and served in positions of increasing responsibility over more than 20 years at Loblaw Companies Ltd. and Fortinos Supermarkets Ltd. Mr. Fortino has received prominent recognition for his contributions, leadership and dedication to the grocery retail sector in Canada, including the 2025 Retail Council of Canada’s Lifetime Achievement Award, 2022 Canada’s Best Executives by Report on Business, 2022 Golden Pencil Award by the Food Industry Association of Canada, and 2021 inductee to the Grocery Business Hall of Fame.

“We are pleased to welcome Carmen to our Board,” said Greg Ramier, Chief Executive Officer of Pet Valu. “As an established and accomplished Canadian retail executive, he will bring valuable operational expertise, with particular strength in commercial execution, supply chain optimization and real estate management.”

“I am excited to join Pet Valu’s Board and help steward the business as it continues to strengthen its leadership in the Canadian pet industry,” said Mr. Fortino. “I look forward to leveraging my experience to help Pet Valu continue to deliver profitable growth and shareholder value over time.”

Pet Valu is also pleased to welcome Matt Reindel to its Board. Subject to approval of the Board and completion of the Company’s process for onboarding new directors, Matt Reindel will be appointed to the Board effective April 1, 2026. Mr. Reindel is an accomplished finance executive with Canadian and international experience in the food retail and consumer-packaged goods sectors. Most recently, he served as Executive Vice President and Chief Financial Officer of Empire Company Limited (TSX: EMP.A). Prior to joining Empire in 2019, Mr. Reindel held several leadership positions at Nestlé for nearly 20 years, including Chief Financial Officer of Nestlé Nutrition North America and Nestlé Food Services for Asia, Oceania and Africa.

“Matt brings extensive finance expertise from a dynamic career across both food retail and consumer packaged goods sectors, with a local and global perspective,” said Mr. Ramier. “We look forward to his contributions and guidance as we shape our strategy over the coming years.”

“I am delighted to join Pet Valu’s Board,” said Mr. Reindel. “As an established Canadian retailer, Pet Valu has a strong legacy of passionately serving Canada’s devoted pet lovers for the last 50 years. I look forward to contributing as the company charts its next chapter of growth.”

In connection with the appointment of Mr. Fortino and Mr. Reindel to the Board, Pet Valu also announces the resignation of Kevin Hofmann as a director of Pet Valu effective January 11, 2026, and Patrick Hillegass’ intention to resign as a director effective March 31, 2026. Mr. Hofmann and Mr. Hillegass were nominees of PV Holdings S.à r.l., Roark Capital Partners II AIV AG, L.P., RCPS Equity Cayman LP and Roark Capital Partners Parallel II AIV AG, L.P. (collectively, the “Former Principal Shareholders”) on the Board pursuant to an investor rights agreement (the “Investor Rights Agreement”) between the Company and the Former Principal Shareholders, which provided the Former Principal Shareholders with certain contractual rights related to, among other things, the nomination of directors of the Company. Effective June 9, 2025, the Former Principal Shareholders had no remaining equity interest in the Company and the Investor Rights Agreement terminated in accordance with its terms. Mr. Hofmann and Mr. Hillegass continued as directors of the Company pending identification by the Board of suitable replacement directors.

“I would like to thank Kevin and Pat for their meaningful contributions to our business over many years, including their active engagement during this transition period,” said Anthony Truesdale, Chair of the Board. “With Carmen and Matt joining our already strong Board, we look forward to continuing to serve our shareholders, franchisees, devoted pet lovers and animal care experts.”

About Pet Valu

Pet Valu is Canada’s leading retailer of pet food and pet-related supplies with over 800 corporate-owned or franchised locations across the country. For more than 45 years, Pet Valu has earned the trust and loyalty of pet parents by offering knowledgeable customer service, an extensive product offering and engaging in-store services. Through its local neighbourhood stores and digital platform, Pet Valu offers more than 10,000 competitively-priced products, including a broad assortment of exclusive, holistic and award-winning proprietary brands. The Company is headquartered in Markham, Ontario and has distribution centres in Brampton, Ontario, Surrey, British Columbia and Calgary, Alberta. Its shares trade on the Toronto Stock Exchange (TSX: PET). To learn more, please visit: www.petvalu.ca.

Forward-Looking Information

Some of the information contained in this press release is forward-looking information, including information regarding the anticipated appointment of Mr. Reindel to the Board and the anticipated resignation of Mr. Hillegass. Forward-looking information is provided as at the date of this press release and is based on management's opinions, estimates and assumptions in light of its experience and perception of historical trends, current trends, current conditions and expected future developments, as well as other factors that management believes appropriate and reasonable in the circumstances. Such forward-looking information is intended to provide information about management's current expectations and plans, and may not be appropriate for other purposes. Pet Valu does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws. Actual results and the timing of events may differ materially from those anticipated in the forward-looking information as a result of various factors and assumptions, and subject to the risks as set out in the Company’s annual information form dated March 3, 2025.

For more information, please contact:

James Allison
Vice President, Investor Relations & Treasury
[email protected]
289-806-4559
2026-01-12 12:09 2mo ago
2026-01-12 07:02 2mo ago
These 3 Small-Cap Stocks Are Built to Weather a Slowdown stocknewsapi
KLIC ROCK UFPT
The Russell 2000 index, commonly referred to as the “small-cap index,” has increased by approximately 6% over the past three months. This rise is mainly driven by changes in interest rates, as the Federal Reserve reduced interest rates by 75 basis points (0.75%) during this period.

Lower interest rates are generally bullish for stocks, but particularly so for small-cap stocks. These companies typically face higher borrowing costs and, therefore, have been acutely sensitive to the higher-for-longer interest rate environment of the past three years.

However, this is also why some analysts think the emerging rally in small caps could last. While it’s unclear how many rate cuts there will be in 2026, it’s almost assuredly not zero. That’s due to the current Fed chair, Jerome Powell’s term expiring in May. The replacement candidate is expected to be more amenable to further cuts.

Get Gibraltar Industries alerts:

Another reason some analysts believe interest rates will fall is the broad uncertainty that continues to hang over the market. It’s an economy that continues to give off mixed signals, even though corporate earnings have been strong.

As rate pressure eases, the best-performing small caps won’t be the most leveraged or speculative, but the ones with strong balance sheets that can convert improving financial conditions into sustainable growth.

UFP Technologies: Quality Growth Without Financial Risk UFP Technologies Today

UFPT

UFP Technologies

$257.51 +2.09 (+0.82%)

As of 01/9/2026 04:00 PM Eastern

52-Week Range$178.26▼

$289.57P/E Ratio29.84

Price Target$289.00

UFP Technologies Inc. NASDAQ: UFPT is part of the industrial stocks sector that performed well in 2025. The company manufactures custom-engineered products using plastics, foams and adhesives for a range of industries, including medical devices, aerospace, defense, electronics, and transportation.

A common thread across all these sectors is that they rely on precision, compliance, and reliability more than price alone. This is reflected in the company’s revenue and earnings, which have been higher year-over-year (YOY). Both the top and bottom lines are projected to grow strongly in 2026.

This also means that, unlike some small-cap companies, UFP Technologies has a strong balance sheet, including consistent free cash flow that allows the company to fund expansion. That means lower interest rates will allow the company to do more of what it already does well.

UFPT stock is basically flat in the last 12 months, but it’s up about 30% in the last three months. The stock recently broke above its 50-day simple moving average, and the MACD is strengthening. However, the relative strength indicator (RSI–not shown) is tipping into overbought territory. That means investors may want to wait for a better entry point before getting involved.

Kulicke & Soffa: Cyclical Upside Backed by Net Cash Kulicke and Soffa Industries Today

KLIC

Kulicke and Soffa Industries

$55.35 +1.40 (+2.59%)

As of 01/9/2026 04:00 PM Eastern

52-Week Range$26.63▼

$55.96Dividend Yield1.48%

Price Target$47.25

The supercycle in chip stocks is expected to continue in 2026. Kulicke & Soffa Industries NASDAQ: KLIC presents investors with an under-the-radar way to play the sector. The company specializes in advanced packaging and manufacturing technologies for semiconductors. That will make it an attractive target for capital expenditure dollars as interest rates move lower.

Kulicke & Soffa has a healthy balance sheet that includes a strong net cash position. Analysts are anticipating a whopping 86% earnings growth over the next 12 months.

KLIC stock has increased by approximately 13.4% over the last 12 months and by 34% in the last three months. It’s also made a strong momentum move in the first five trading days of 2026. That puts the stock price near the top of its 52-week range. Analysts are generally bullish, but the stock may have some downward pressure on it in the near term.

Gibraltar Industries: Rate Sensitivity Without Leverage Gibraltar Industries Today

ROCK

Gibraltar Industries

$53.05 +1.49 (+2.89%)

As of 01/9/2026 04:00 PM Eastern

52-Week Range$42.86▼

$75.08P/E Ratio663.21

Gibraltar Industries Inc. NASDAQ: ROCK is a play on infrastructure. The company would seem to be a beneficiary of lower interest rates. However, the opposite has played out with ROCK stock, which is down about 23% since the Fed’s rate-cutting campaign began.

That appears to be largely due to a delayed controlled environment agriculture project that raised concerns about the stock’s valuation. However, that’s a short-term headwind, and the company is reporting an expanding project backlog. That should begin to show up in the company’s top and bottom lines, particularly in the second half of 2026.

Investors also benefit from the company's conservative capital structure, which allows it to navigate slowdowns without being forced into asset sales or dilutive equity issuance. As financing becomes more accessible, Gibraltar is positioned to benefit from improving construction and infrastructure activity while maintaining financial discipline.

Should You Invest $1,000 in Gibraltar Industries Right Now?Before you consider Gibraltar Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gibraltar Industries wasn't on the list.

While Gibraltar Industries currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
2026-01-12 12:09 2mo ago
2026-01-12 07:03 2mo ago
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares stocknewsapi
SR
January 12, 2026 07:03 ET  | Source: Dimensional Fund Advisors Ltd

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.KEY INFORMATION   (a)Full name of discloser:Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offereeSpire Healthcare Group PLC (d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure09 January 2026 (f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”N/a   2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE   If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)   Class of relevant security:1p ordinary (GB00BNLPYF73)  InterestsShort Positions  Number%Number% (1)Relevant securities owned and/or controlled:12,350,6023.07 %   (2)Cash-settled derivatives:     (3)Stock-settled derivatives (including options) and agreements to purchase/sell:      Total12,350,602 *3.07 %   * Dimensional Fund Advisors LP and/or its affiliates do not have discretion regarding voting decisions in respect of 35,234 shares that are included in the total above.   All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

     (b)Rights to subscribe for new securities (including directors’ and other employee options)   Class of relevant security in relation to which subscription right exists:  Details, including nature of the rights concerned and relevant percentages:    3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE   Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.

 (a)Purchases and sales   Class of relevant securityPurchase/saleNumber of securitiesPrice per unit 1p ordinary (GB00BNLPYF73)Sale9,0091.7102 GBP There was a Transfer In of 24,108 shares of 1p ordinary   (b)Cash-settled derivative transactions   Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit         (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit          (ii)Exercise   Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit         (d)Other dealings (including subscribing for new securities)        Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)        4.OTHER INFORMATION   (a)Indemnity and other dealing arrangements   Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None   (b)Agreements, arrangements or understandings relating to options or derivatives   Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none” None   (c)Attachments   Is a Supplemental Form 8 (Open Positions) attached?NO   Date of disclosure12 January 2026 Contact nameThomas Hone Telephone number+44 20 3033 3419    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
2026-01-12 12:09 2mo ago
2026-01-12 07:03 2mo ago
US judge to consider Orsted's challenge to Trump offshore wind pause stocknewsapi
DNNGY DOGEF
A drone view shows rotor blades and other parts for the ongoing construction of the Revolution Wind offshore wind turbine farm, staged on the State Pier in New London, Connecticut, U.S.,... Purchase Licensing Rights, opens new tab Read more

CompaniesJan 12 (Reuters) - A U.S. judge on Monday will consider a request from Danish energy company Orsted (ORSTED.CO), opens new tab for an injunction against the Trump administration's decision to halt its $5 billion Revolution Wind project off the coast of Rhode Island.

The company's lawsuit is one of several filed by offshore wind companies and states seeking to reverse the Interior Department's December 22 suspension of five offshore wind leases over what it said were national security concerns.

Sign up here.

Offshore wind developers have faced repeated disruptions to multi-billion dollar projects under U.S. President Donald Trump, who has said he finds wind turbines ugly, expensive and inefficient.

The project is about 87% complete and is expected to begin generating power this year, Orsted has said.

Revolution Wind LLC is a 50-50 joint venture between Orsted and Global Infrastructure Partners' Skyborn Renewables. Orsted has also sued on behalf of its Sunrise Wind project off the coast of New York.

Monday's hearing is the first of three preliminary injunction hearings that will be held this week in lawsuits seeking to block the offshore wind pause. The others involve Equinor's Empire Wind, off the coast of New York, and Dominion's Coastal Virginia Offshore Wind facility.

Reporting by Nichola Groom; Editing by Edmund Klamann

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-01-12 12:09 2mo ago
2026-01-12 07:04 2mo ago
ECARX Holdings Inc. Announces US$45.6 million Strategic Investment from Geely Holding Group stocknewsapi
ECX
, /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a global mobility tech provider, today announced that it has entered into a subscription agreement with Geely Investment Holding Ltd. ("Geely Holding") on January 8th, 2026. Under the terms of the agreement, Geely Holding has agreed to subscribe for and purchase from the Company, through a private placement, a total of 27,297,002 newly issued Class A ordinary shares of the Company at a price of US$1.67 per ordinary share, for a total purchase price of US$45.6 million. The per share price is equal to the volume-weighted average price of the ordinary shares of the Company on Nasdaq for the 20 consecutive trading days immediately preceding the date of the agreement. The closing of the private placement is subject to customary closing conditions and is expected to take place in the near future. The ordinary shares to be purchased by Geely Holding in with this private placement will be subject to a six-month lock-up period with certain customary exceptions.

ECARX intends to use the net proceeds from the offering to accelerate the development of its cutting-edge vehicle hardware and software solutions and scale their deployment to fuel its global expansion, while further strengthening its financial position and liquidity.

Daniel Donghui Li, Executive Vice Chairman of Geely Holding Group, stated: "ECARX has established itself as a key technology partner in the global automotive industry, and this investment underscores Geely's continued confidence in the company's long-term vision and technological capabilities. We believe ECARX's innovative solutions will play an increasingly important role in shaping the future of smart, connected vehicles worldwide."

Mr. Ziyu Shen, Chief Executive Officer and Chairman of ECARX, commented, "Following the two project wins from Volkswagen Group last year and our deepened strategic partnership with Lotus Tech, this investment will support the build out of our R&D hub in Germany and infrastructure across key growth markets in South America and Southeast Asia, providing us with the R&D, delivery, and supply chain capabilities to fuel our global expansion. Geely Holding's commitment underscores their strong confidence in our fundamentals at a time when our share price does not fully reflect the long-term opportunities ahead of us. We view this investment as a powerful endorsement of our global strategy and proven ability to capitalize on accelerating demand. As we kick off 2026, we look forward to working closely together to sustain growth momentum."

The securities offered in this private placement have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ECARX Holdings Inc.

ECARX (Nasdaq: ECX) is a global automotive technology provider with capabilities to deliver turnkey solutions for next‑generation smart vehicles, from the system‑on‑a‑chip (SoC) to central computing platforms and software. As automakers develop new vehicle architectures, ECARX is developing full‑stack solutions to enhance the user experience while reducing complexity and cost.

Founded in 2017 and listed on Nasdaq in 2022, ECARX now has over 1,500 employees based in 13 major locations in China, UK, USA, Brazil, Singapore, Malaysia, Sweden and Germany. To date, ECARX products can be found in approximately 10 million vehicles worldwide.

Forward-Looking Statements

This release contains statements that are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's beliefs and expectations as well as on assumptions made by and data currently available to management, appear in a number of places throughout this document and include statements regarding, amongst other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. The use of words "expects", "intends", "anticipates", "estimates", "predicts", "believes", "should", "potential", "may", "preliminary", "forecast", "objective", "plan", or "target", and other similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties that could cause actual results to differ materially, including, but not limited to statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, and the markets in which we operate.

For a discussion of these and other risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statement, see ECARX's filings with the U.S. Securities and Exchange Commission. ECARX undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

SOURCE ECARX Holdings Inc.
2026-01-12 12:09 2mo ago
2026-01-12 07:05 2mo ago
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance stocknewsapi
KIDS
January 12, 2026 07:05 ET  | Source: OrthoPediatrics Corp.

Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior year
Initiates guidance for record Adjusted EBITDA in 2026

WARSAW, Ind., Jan. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December 31, 2025, issued 2026 financial guidance, and provided business updates.

Recent Business and Financial Highlights:

Helped over 37,500 children in the fourth quarter 2025, with the Company now having helped nearly 1.3 million children since inception.Generated record preliminary unaudited full year 2025 net revenue of $236.1 million, representing continued growth compared to $204.7 million in 2024 of 15%. Preliminary full year domestic net revenue is expected to be $186.2 million, representing 16% annual growth and international net revenue is expected to be $49.9 million, representing 15% annual growth.Generated preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, representing 16% growth compared to $52.7 million in the fourth quarter of 2024. Preliminary domestic fourth quarter net revenue is expected to be $48.4 million, representing 13% growth compared to the prior year period, and international net revenue is expected to be $12.9 million, representing 32% growth compared to the prior year period.Generated approximately $6.0 - $7.0 million dollars of fourth quarter 2025 free cash flow, resulting in total year 2025 free cash flow usage being over 50% lower than total year 2024.Received EUMDR certification for Response Spine 4.5/5.0 and 5.5/6.0, as well as trauma and deformity plates, screws, intramedullary nails, and related instruments. 2026 Financial Guidance
OrthoPediatrics projects 2026 revenue to be in the range of $262 million to $266 million, representing 11% to 13% growth compared to full year 2025 preliminary unaudited net revenue. The Company also expects approximately $10 million annual set deployment and expects to generate approximately $25 million Adjusted EBITDA in 2026.

“Throughout 2025, we delivered another year of strong performance, advanced our strategic initiatives, and widened our leadership position in pediatric orthopedics. Our Trauma and Deformity and Scoliosis implant businesses continued to execute effectively, taking market share, driving topline revenue, and improving profitability,” commented David Bailey, President & CEO of OrthoPediatrics. “We are also extremely pleased with the specialty bracing (OPSB) business, which remains a tremendous market opportunity and a strategic catalyst for deepening customer relationships. OPSB is proving to be a capital-efficient driver of both revenue and earnings, and we are only beginning to unlock its full potential as we scale in the years ahead. In 2025, we helped over 37,500 children in the fourth quarter alone and nearly 1.3 million since inception, while generating record preliminary unaudited revenue growth of 15% from 2024, and significantly reducing free cash flow usage year-over-year. Looking forward, we are confident that our growth drivers and operational discipline position us to execute on our long-term outlook and continue making a meaningful impact for children worldwide.”

The Company plans to release its fourth quarter and full year 2025 financial results and provide additional commentary on its financial outlook in late February to early March. The quarterly and annual preliminary unaudited net revenue estimates for 2025 included in this press release are prior to the completion of review and audit procedures by the Company’s independent registered public accounting firm and are therefore subject to adjustment.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential," "objective," "would" and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and the other risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 5, 2025, as updated and supplemented by our other SEC reports filed from time to time, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 85 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Trip Taylor
Gilmartin Group
[email protected]
415-937-5406
2026-01-12 12:09 2mo ago
2026-01-12 07:05 2mo ago
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer stocknewsapi
JAZZ
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical collaboration with Jazz Pharmaceuticals (Nasdaq: JAZZ) on the exploration of a novel combination therapy for patients with HER2-positive breast cancer. As part of this collaboration, the partners will initiate a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial, evaluating the combination of Boehringer’s zongertinib and Jazz’s zanidatamab in breast cancer.

Despite significant progress in HER2-targeted therapies, HER2-positive breast cancer remains an aggressive subtype, accounting for approximately 15–20% of all breast cancers. Advanced or metastatic patients still have poor five-year survival rates, around 50%. This collaboration aims to improve patient outcomes by combining two differentiated HER2-targeted approaches, potentially offering a new therapeutic option for patients.

“At Boehringer Ingelheim, we are committed to pushing the boundaries of science to deliver innovative solutions for patients with high unmet need,” said Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim. “By combining zongertinib’s precision approach with zanidatamab’s unique bispecific antibody mechanism, we aim to unlock new possibilities for patients living with HER2-expressing breast cancer.”

Amal Melhem-Bertrandt, VP, Oncology Therapy Area Head and Zanidatamab Global Clinical Lead at Jazz Pharmaceuticals., said, “This research collaboration with Boehringer Ingelheim is centered in our shared vision to transform treatment paradigms in HER2-expressing breast cancer through the investigation of this novel HER2-targeted combination therapy, as well as possible opportunities to advance outcomes in multiple tumor types.”

HERNEXEOS® (zongertinib tablets) recently received FDA (accelerated) approval in the U.S., CDE (conditional) approval in China, and PMDA marketing authorization in Japan as the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). In the Beamion LUNG-1 trial, zongertinib demonstrated an objective response rate (ORR) of 71% specifically in pre-treated patients with HER2-mutant NSCLC, along with durable responses. Zongertinib is also under investigation in ongoing clinical trials for various HER2-driven tumors.

ZIIHERA® (zanidatamab), a bispecific HER2-directed antibody, has received accelerated approval from the U.S. FDA for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Further, it is currently in Phase III trials for GEA, BTC and metastatic breast cancer, and is also being investigated in earlier lines of therapy in other tumor types.

The companies anticipate that this study will generate critical insights into the safety and efficacy of dual HER2 blockade and inform the development of a potential future combination therapy.

Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.

Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
2026-01-12 12:09 2mo ago
2026-01-12 07:05 2mo ago
Invitation to HMS Networks' fourth quarter conference call 2025 stocknewsapi
HMNKF
HMS Networks AB (publ) will release its fourth quarter report of 2025 on Tuesday January 27th, 2026, at 07.30 CET.

On the same day, at 09.00 CET, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts.

The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference.

If you wish to participate via webcast, please use the link below.

Link to webcast

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

Link to teleconference

The presentation and recording of the telephone conference will be available on HMS’ website after the call.

For more information, please contact:
Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01
Joakim Nideborn, CFO HMS, +46 (0)35 710 69 83

HMS Networks AB (publ) is a market-leading provider of solutions in Industrial Information and Communication Technology (Industrial ICT) and employs over 1,100 people. Local sales and support are handled through over 20 sales offices all over the world, as well as through a wide network of distributors and partners. HMS reported sales of SEK 3,059 million in 2024 and is listed on the NASDAQ OMX in Stockholm in the Large Cap segment and Telecommunications sector.

PRM - HMS Invitation to the fourth quarter 2025 conference call
2026-01-12 12:09 2mo ago
2026-01-12 07:06 2mo ago
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares stocknewsapi
JTGPF
January 12, 2026 07:06 ET  | Source: Dimensional Fund Advisors Ltd

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.KEY INFORMATION   (a)Full name of discloser:Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offereeJust Group PLC (d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure09 January 2026 (f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”N/a   2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE   If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)   Class of relevant security:10p ordinary (GB00BCRX1J15)  InterestsShort Positions  Number%Number% (1)Relevant securities owned and/or controlled:24,708,1132.38 %   (2)Cash-settled derivatives:     (3)Stock-settled derivatives (including options) and agreements to purchase/sell:      Total24,708,113 *2.38 %   * Dimensional Fund Advisors LP and/or its affiliates do not have discretion regarding voting decisions in respect of 51,686 shares that are included in the total above.   All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

     (b)Rights to subscribe for new securities (including directors’ and other employee options)   Class of relevant security in relation to which subscription right exists:  Details, including nature of the rights concerned and relevant percentages:    3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE   Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.

 (a)Purchases and sales   Class of relevant securityPurchase/saleNumber of securitiesPrice per unit 10p ordinary (GB00BCRX1J15)Sale3,6032.1750 GBP There was a Transfer In of 2,935 shares of 10p ordinary   (b)Cash-settled derivative transactions   Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit         (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit          (ii)Exercise   Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit         (d)Other dealings (including subscribing for new securities)        Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)        4.OTHER INFORMATION   (a)Indemnity and other dealing arrangements   Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None   (b)Agreements, arrangements or understandings relating to options or derivatives   Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none” None   (c)Attachments   Is a Supplemental Form 8 (Open Positions) attached?NO   Date of disclosure12 January 2026 Contact nameThomas Hone Telephone number+44 20 3033 3419    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
2026-01-12 12:09 2mo ago
2026-01-12 07:06 2mo ago
Kyivstar Launches 5G Pilot Program in Lviv stocknewsapi
KYIV
January 12, 2026 07:06 ET  | Source: Kyivstar Group Ltd

KYIV, Ukraine, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyivstar (Nasdaq: KYIV; KYIVW), Ukraine's leading digital operator, has launched a 5G test zone in the historical center of Lviv, Ukraine. This marks the company’s first local pilot 5G project, implemented within a framework established by the Ministry of Digital Transformation of Ukraine.

The goal of the pilot project is to evaluate the performance of the new technology under real urban conditions. Following a successful evaluation, Kyivstar will gradually expand 5G coverage to other Ukrainian cities, including Kharkiv and Borodianka, with Kyiv and Odesa planned for 2026. The Ukraine government determined the testing locations, selecting the most populous cities with advanced infrastructure. A full-scale 5G rollout across Ukraine will only be possible after the war ends.

“Even in the midst of full-scale war — under constant Russian attacks on infrastructure and during blackouts — Ukraine continues to move forward and expand innovation in the telecom sector. The launch of the 5G pilot in Lviv is an important step that we have jointly prepared with mobile operators. Lviv is only the first city. We will soon begin pilots in Borodianka and Kharkiv as well. Our goal is to ensure that Ukrainians stay connected and have access to advanced technologies under any circumstances,” said Mykhailo Fedorov, First Deputy Prime Minister - Minister of Digital Transformation of Ukraine.

“Kyivstar is driving Ukraine’s digital transformation with investments in advanced technologies, from piloting 5G in Lviv to pioneering Direct to Cell satellite connectivity through is partnership with Starlink,” said Oleksandr Komarov, CEO of Kyivstar. “Our commitment goes beyond connectivity: we are investing USD 1 billion over 2023-2027 into rebuilding Ukraine’s connectivity and digital infrastructure, from energy resilience for our network to digital services to Ukraine’s own sovereign Ukrainian LLM, powering not just growth for our company but helping support Ukraine’s future recovery.”

The base stations of this new-to-Ukraine standard have already been put into operation in Lviv’s historical downtown. Prior to the pilot launch, Kyivstar carried out comprehensive preparations across its network infrastructure, including ensuring that the 5G activation would not interfere with military communications. The company conducted its first 5G tests in February 2024 at its head office in Kyiv, confirming its technical readiness for broader deployment. In Ukraine, 5G will operate in two frequency bands — 3500 MHz (for high data transmission speeds) and 700 MHz (to ensure wider coverage).

During pre-launch testing in Lviv, Kyivstar’s 5G network achieved peak download speeds exceeding 2.4 Gbps (actual speeds after commercial launch may vary depending on network congestion and other environmental factors).

Kyivstar will continue to focus on its “4G Everywhere” target, which meets the needs of most smartphone users in Ukraine. With Kyivstar’s ongoing network modernization, peak 4G speeds already exceed 1 Gbps in some areas during off-peak hours.

About Kyivstar Group Ltd.
Kyivstar Group Ltd. (“Kyivstar”, the “Group”) is a Nasdaq-listed holding company that operates JSC Kyivstar, the country’s leading digital operator and the first Ukrainian company to have its shares traded on a U.S. stock exchange.
The Group’s companies provide a broad range of connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as Big Data, cloud, and cybersecurity.
Together with VEON, Kyivstar intends to invest USD 1 billion in Ukraine between 2023-2027, through social investments in infrastructure and technological development, charitable donations and strategic acquisitions.
For more information, please visit https://investors.kyivstar.ua.
Nasdaq tickers: KYIV; KYIVW

About JSC Kyivstar
JSC Kyivstar is Ukraine’s leading digital operator, serving more than 22.5 million mobile customers and over 1.2 million home internet fixed line customers as of September 30, 2025. The company provides services using a wide range of mobile and fixed technologies, including 4G, Big Data, cloud solutions, cybersecurity services, digital TV, and more. JSC Kyivstar is advancing new telecommunication technologies in Ukraine and together with VEON plans to invest USD 1 billion in this direction between 2023–2027.
The company contributes to overcoming the challenges of wartime and, over the past three years, has allocated more than UAH 3.4 billion to support the Defense Forces, its subscribers, and the implementation of social projects. Kyivstar has operated in Ukraine for 27 years and is recognized as the largest taxpayer in the digital communications market, a top employer, and a socially responsible company.
Additional information: [email protected], www.kyivstar.ua.

Disclaimer
This press release contains “forward-looking statements,” as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to, among other things, Kyivstar’s 5G Pilot Program and development plans as well as Kyivstar Group’s ability to achieve anticipated results and business objectives. There are numerous risks and uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to Kyivstar’s 5G Pilot Program and development plans as well as Kyivstar Group’s ability to achieve anticipated results and business objectives, among others discussed in the section entitled “Risk Factors” included in the final prospectus filed by Kyivstar Group with the U.S. Securities and exchange Commission (“SEC”) on December 18, 2025, as amended and supplemented from time to time, and in any other subsequent filings with the SEC by Kyivstar Group.
2026-01-12 12:09 2mo ago
2026-01-12 07:08 2mo ago
Dividend ETFs: More Than One Way to Diversify for Income stocknewsapi
NOBL SPYD XUDV
The ETF universe continued to expand in 2025, with a growing number of high-income products incorporating options strategies to enhance payouts. However, for many investors and advisors, traditional ETFs that own dividend-paying stocks remain a core component of a well-rounded portfolio.

According to S&P Dow Jones Indices, dividend growth slowed during the fourth quarter of 2025. Corporate boards appeared more cautious about forward cash commitments, likely influenced by uncertainty surrounding tariff policies, rising costs, and fluctuating consumer and enterprise spending. While the majority of companies continued to increase their dividends, the size of those raises was generally smaller. For the S&P 500, dividend payments grew by 2.2% compared to the previous year.

Identifying the Dividend Drivers While over 80% of S&P 500 companies pay a dividend, the commitment to higher payouts in 2025 was concentrated in specific areas. The Financials and Industrials sectors led the way, with each sector recording 68 positive dividend actions. This represented a significant majority of their constituents—89% and 85%, respectively. Among sectors with smaller overall market weights, Real Estate and Utilities also performed well, contributing 32 and 28 positive dividend actions.

A Tale of Three Strategies There are many dividend ETFs available to investors, and even those using the same parent index can provide vastly different exposures.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) focuses on quality and longevity, requiring holdings to have raised dividends for at least 25 consecutive years. This leads to a heavy concentration in “old economy” sectors like Industrials and Consumer Staples.

In contrast, the SPDR Portfolio S&P 500 High Dividend ETF (SPYD) prioritizes current yield. It targets approximately 80 of the highest-yielding names in the index, which results in a significant tilt toward Real Estate and a minimal footprint in Technology.

Finally, the Franklin U.S. Dividend Booster Index ETF (XUDV), which will cross its one-year anniversary later this month, offers a unique optimization process. It seeks to maximize yield while specifically managing for volatility and concentration risks. Its portfolio is led by Financials (23%), Consumer Staples (15%), and Health Care (10%), featuring names like Kraft Heinz, Pfizer, and United Parcel Service.

The table below illustrates how these different objectives result in distinct sector profiles:

Performance and Yield Nuances The structural differences between these funds led to diverging results in 2025. SPYD’s 4.4% dividend yield was double that of NOBL, and its 0.07% expense ratio is significantly lower. However, NOBL’s 6.8% total return was more than 200 basis points stronger than SPYD’s, proving that dividend growth and sector tailwinds can often outperform raw yield. XUDV does not have a full year 2025 record.

However, XUDV’s 5.2% yield and 0.09% expense ratio offer a compelling middle ground for those seeking a modernized approach to income. As always, looking under the hood is essential to ensure a fund’s sector bets align with your market outlook.

For more news, information, and analysis, visit the Thematic Investing Content Hub. 

VettaFi LLC (“VettaFi”) is the index provider for XUDV, for which it receives an index licensing fee. However, XUDV is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of XUDV.`

Earn free CE credits and discover new strategies
2026-01-12 11:09 2mo ago
2026-01-12 06:00 2mo ago
NioCorp Provides Preliminary Unaudited Financial Results for the Three- and Six-Month Periods Ended December 31, 2025 stocknewsapi
NB
CENTENNIAL, CO / ACCESS Newswire / January 12, 2026 / NioCorp Developments Ltd. ("NioCorp," "our," or the "Company") (NASDAQ:NB) today provided its preliminary unaudited financial results for the three- and six-month periods ended December 31, 2025.

As of December 31, 2025, the Company had a record cash balance of $307 million following a period of significant derisking of the Elk Creek Critical Minerals Project (the "Project"). During the six-month period, the U.S. Department of Defense awarded Elk Creek Resources Corp. up to $10 million to support certain activities related to the Elk Creek Critical Minerals Project; NioCorp completed an infill drilling campaign for the Project; closed on the acquisition of scandium alloy manufacturing assets of FEA Materials LLC; completed land purchases necessary to secure ownership of all land needed for the Project; and entered into agreements with the U.S. Department of Defense and Lockheed Martin related to scandium-based technologies for potential defense applications.

The Company's results for the three- and six-month periods ended December 31, 2025 are presented below. Certain information in the following discussion is presented on a Non-GAAP basis, including adjusted net loss and adjusted net loss per share.

The Company reported a net loss of $0.8 million, or $0.02 per share, compared to a net loss of $0.5 million, or $0.01 per share, for the three months ended December 31, 2024. On an adjusted basis, the Company reported an adjusted net loss of $5.3 million, or $0.06 per share, compared to an adjusted net loss of $1.9 million, or $0.05 per share, for the prior-year period.¹

The Company reported a net loss of $43.4 million, or $0.44 per share, compared to a net loss of $2.5 million, or $0.06 per share, for the six months ended December 31, 2024. On an adjusted basis, the Company reported an adjusted net loss of $13.6 million, or $0.15 per share, compared to an adjusted net loss of $3.3 million, or $0.08 per share, for the prior-year period.¹

The net loss for the three months ended December 31, 2025 primarily reflects non-cash gains of approximately $5.9 million related to earnout shares and warrants classified as liabilities on the consolidated balance sheet, driven by a slight decrease in the closing price of the Company's common shares between September 30, 2025 and December 31, 2025. The net loss for the six months ended December 31, 2025 primarily reflects non-cash losses of approximately $26.1 million related to earnout shares and warrants classified as liabilities on the consolidated balance sheet, driven by appreciation of the Company's common shares between June 30, 2025 and December 31, 2025.

NioCorp continues as a development stage company and our operating cash outflows for the six-month period totaled $7.6 million. The increase in adjusted net losses for the three- and six-month periods ended December 31, 2025 primarily reflects expenditures associated with the Company's Elk Creek drilling program and its current feasibility study update efforts.

NioCorp intends to file its unaudited interim condensed consolidated financial statements for the three- and six-month periods ended December 31, 2025 in its Quarterly Report on Form 10-Q on or before February 16, 2026.

1Non-GAAP Measures

The following table presents a reconciliation of the Company's GAAP financial measures to the non-GAAP financial measures referenced above.

NIOCORP DEVELOPMENTS LTD.

RECONCILIATION OF GAAP FINANCIAL MEASURES TO

NON-GAAP FINANCIAL MEASURES

(Unaudited - dollars in thousands, except per share amounts)

For the Three Months Ended December 31,

For the Six Months Ended December 31,

2025

2024

2025

2024

Net (loss) and comprehensive (loss) attributable to the Company

$

(751

)

$

(450

)

$

(43,410

)

$

(2,521

)

Adjustments:

Change in fair value of earnout liability

(4,188

)

(1,569

)

10,308

(753

)

Change in fair value of warrant liability

(1,732

)

(837

)

15,826

(893

)

Share based compensation

1,075

781

3,377

781

Non-recurring gains

-

-

-

(122

)

Other non-cash items

281

204

282

222

Adjusted net Loss

$

(5,315

)

$

(1,871

)

$

(13,617

)

$

(3,286

)

Net loss per common share attributable to the Company

$

(0.02

)

$

(0.01

)

$

(0.44

)

$

(0.06

)

Adjustments:

Change in fair value of earnout liability

(0.04

)

(0.04

)

0.11

(0.02

)

Change in fair value of warrant liability

(0.01

)

(0.02

)

0.17

(0.02

)

Share based compensation

0.01

-

0.04

0.02

Nonrecurring gains

-

-

-

-

Other noncash items

-

-

-

-

Adjusted loss per common share

$

(0.06

)

$

(0.05

)

$

(0.15

)

$

(0.08

)

The Company has included certain non-GAAP financial measures in this press release such as adjusted net loss and adjusted net loss per share. Adjusted net loss for presentation purposes is our net loss plus non-cash items plus (gain)/loss on non-recurring items. These non-GAAP measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). Because these non-GAAP performance measures do not have any standardized meaning prescribed by U.S. GAAP, they may not be comparable to similar measures presented by other companies. The Company's management believes that presenting adjusted net loss and adjusted net loss per share provides investors with additional insight into underlying operating performance by excluding the non-cash gains and losses noted above. Our presentation of certain non-GAAP financial measures should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculations of non-GAAP measures. These non-GAAP measures are not presented in accordance with U.S. GAAP and the use of these terms vary from others in our industry.

All figures reported above with respect to the three- and six-month periods ended December 31, 2025, are preliminary and are unaudited and subject to change and adjustment as the Company prepares its unaudited interim condensed consolidated financial statements for the three- and six-month periods ended December 31, 2025 and 2024. Accordingly, investors are cautioned not to place undue reliance on the foregoing information. The Company does not intend to provide preliminary results on a regular basis in the future. The preliminary results provided in this news release constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, are based on several assumptions and are subject to a number of risks and uncertainties. Actual results may differ materially. See "Forward-looking Statements."

# # #

FOR MORE INFORMATION:

Jim Sims, Corporate Communications Officer, NioCorp Developments Ltd., (720) 334-7066, [email protected]

Alex Guthrie, Director, Investor Relations, NioCorp Developments Ltd., (647) 999-0527, [email protected]

@NioCorp $NB #Niobium #Scandium #rareearth #neodymium #dysprosium #terbium #ElkCreek

ABOUT NIOCORP

NioCorp is developing the Elk Creek Project that is expected to produce niobium, scandium, and titanium. The Company also is evaluating the potential to produce several rare earths from the Elk Creek Project. Niobium is used to produce specialty alloys as well as High Strength, Low Alloy steel, which is a lighter, stronger steel used in automotive, structural, and pipeline applications. Scandium is a specialty metal that can be combined with Aluminum to make alloys with increased strength and improved corrosion resistance. Scandium is also a critical component of advanced solid oxide fuel cells. Titanium is used in various lightweight alloys and is a key component of pigments used in paper, paint and plastics and is also used for aerospace applications, armor, and medical implants. Magnetic rare earths, such as neodymium, praseodymium, terbium, and dysprosium are critical to the making of neodymium-iron-boron magnets, which are used across a wide variety of defense and civilian applications.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable Canadian securities laws (collectively "forward-looking statements"). Forward-looking statements may include, but are not limited to, statements regarding our preliminary financial results, and the timing of the filing of the unaudited interim condensed consolidated financial statements for the three- and six-month periods ended December 31, 2025; our progress toward updating the feasibility study for the Elk Creek Project; NioCorp's expectation of producing niobium, scandium, and titanium, and the potential of producing rare earths, at the Elk Creek Project; and NioCorp's ability to secure sufficient project financing to complete construction of the Elk Creek Project and move it to commercial operation. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of NioCorp and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to: NioCorp's ability to receive sufficient project financing for the construction of the Elk Creek Project on acceptable terms, or at all; the future price of and demand for metals, including Al-Sc alloy; and the stability of the financial and capital markets. Such expectations and assumptions are inherently subject to uncertainties and contingencies regarding future events and, as such, are subject to change. Forward-looking statements involve a number of risks, uncertainties or other factors that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made by NioCorp with the Securities and Exchange Commission and with the applicable Canadian securities regulatory authorities and the following: NioCorp's requirement of significant additional capital; NioCorp's ability to receive sufficient project financing for the construction of the Elk Creek Project on acceptable terms, or at all; NioCorp's ability to achieve the required milestones and receive the full $10.0 million in reimbursement under the U.S. Department of Defense Award; NioCorp's ability to receive a final commitment of financing from the Export-Import Bank of the United States or other debt financing or financial support on acceptable timelines, on acceptable terms, or at all; NioCorp's ability to access the full amount of the expected net proceeds under the Yorkville Equity Facility Financing Agreement; NioCorp's ability to continue to meet the listing standards of The Nasdaq Stock Market LLC; risks relating to NioCorp's common shares, including price volatility, lack of dividend payments and dilution or the perception of the likelihood of any of the foregoing; the extent to which NioCorp's level of indebtedness and/or the terms contained in agreements governing NioCorp's indebtedness, if any, the Yorkville Equity Facility Financing Agreement or other agreements may impair NioCorp's ability to obtain additional financing, on acceptable terms, or at all; covenants contained in agreements with NioCorp's secured creditors that may affect its assets; NioCorp's limited operating history; NioCorp's history of losses; the material weaknesses in NioCorp's internal control over financial reporting, NioCorp's efforts to remediate such material weaknesses and the timing of remediation; the possibility that NioCorp may qualify as a passive foreign investment company under the U.S. Internal Revenue Code of 1986, as amended (the "Code"); the potential that the business combination with GX Acquisition Corp. II and other related transactions could result in NioCorp becoming subject to materially adverse U.S. federal income tax consequences as a result of the application of Section 7874 and related sections of the Code; cost increases for NioCorp's exploration and, if warranted, development projects; a disruption in, or failure of, NioCorp's information technology systems, including those related to cybersecurity; equipment and supply shortages; variations in the market demand for, and prices of, niobium, scandium, titanium and rare earth products; current and future offtake agreements, joint ventures, and partnerships, including NioCorp's ability to negotiate extensions to existing agreements or to enter into new agreements, on favorable terms or at all; NioCorp's ability to attract qualified management; estimates of mineral resources and reserves; mineral exploration and production activities; feasibility study results; the results of metallurgical testing; the results of technological research; changes in demand for and price of commodities (such as fuel and electricity) and currencies; competition in the mining industry; changes or disruptions in the securities markets; legislative, political or economic developments, including changes in federal and/or state laws that may significantly affect the mining and scandium alloy industries; trade policies and tensions, including tariffs; inflationary pressures; the impacts of climate change, as well as actions taken or required by governments related to strengthening resilience in the face of potential impacts from climate change; the need to obtain permits and comply with laws and regulations and other regulatory requirements; the timing and reliability of sampling and assay data; the possibility that actual results of work may differ from projections/expectations or may not realize the perceived potential of NioCorp's projects; risks of accidents, equipment breakdowns, and labor disputes or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in development programs; operating or technical difficulties in connection with exploration, mining, development or scandium alloy production activities; management of the water balance at the Elk Creek Project site; land reclamation requirements related to the Elk Creek Project; the speculative nature of mineral exploration and development, including the risks of diminishing quantities of grades of reserves and resources; claims on the title to NioCorp's properties; the infringement or loss of NioCorp's intellectual property rights; potential future litigation; and NioCorp's lack of insurance covering all of NioCorp's operations.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of NioCorp prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning the matters addressed herein and attributable to NioCorp or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Except to the extent required by applicable law or regulation, NioCorp undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE: NioCorp Developments Ltd.